ADPKD PATIENT HANDBOOK
Understanding and living with autosomal dominant polycystic kidney disease
Originally created by: Irene Duley, RN ANP and Patricia Gabow, MD
University of Colorado Health Sciences Center and Denver Hospital

Revised and updated 2015:

York Pei, MD
Director, Hereditary Kidney Disease Clinic
University Health Network
Toronto, Canada

Terry Watnick, MD
Baltimore PKD Research and Clinical Core Center
Associate Professor, Division of Nephrology
University of Maryland School of Medicine
Baltimore, Maryland

John Bissler, MD
Director, Division of Nephrology at St. Jude Children's Research Hospital and LeBonheur Children's Hospital
Professor of Pediatrics
Director, Tuberous Sclerosis Center of Excellence

Revised and updated 2018:

Neera Dahl, MD, PhD
Associate Professor of Medicine
Yale School of Medicine, Section of Nephrology

Frederic F. Rahbari-Oskoui, MD, MS, FASN
Associate Professor of Medicine
Emory University School of Medicine
Renal Division

This handbook made possible by an education grant from Otsuka America Pharmaceutical, Inc.
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>About PKD</td>
<td>6</td>
</tr>
<tr>
<td>DNA testing</td>
<td>7</td>
</tr>
<tr>
<td>What to know about kidneys</td>
<td>9</td>
</tr>
<tr>
<td>Your kidney is a filter</td>
<td>9</td>
</tr>
<tr>
<td>Waste products cleared by the kidneys</td>
<td>9</td>
</tr>
<tr>
<td>Hormones and your kidneys</td>
<td>10</td>
</tr>
<tr>
<td>Cysts in the kidney</td>
<td>11</td>
</tr>
<tr>
<td>Diagnostic tests for PKD</td>
<td>14</td>
</tr>
<tr>
<td>Blood tests</td>
<td>14</td>
</tr>
<tr>
<td>Urine tests</td>
<td>14</td>
</tr>
<tr>
<td>Imaging tests</td>
<td>15</td>
</tr>
<tr>
<td>PKD genetics</td>
<td>16</td>
</tr>
<tr>
<td>Signs and symptoms of PKD</td>
<td>21</td>
</tr>
<tr>
<td>High blood pressure (hypertension)</td>
<td>21</td>
</tr>
<tr>
<td>Kidney pain</td>
<td>22</td>
</tr>
<tr>
<td>Blood in the urine</td>
<td>23</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>23</td>
</tr>
<tr>
<td>Kidney stones</td>
<td>24</td>
</tr>
<tr>
<td>Stages of chronic kidney disease</td>
<td>25</td>
</tr>
<tr>
<td>CKD in PKD</td>
<td>25</td>
</tr>
<tr>
<td>How to take care of yourself</td>
<td>27</td>
</tr>
<tr>
<td>Diet</td>
<td>27</td>
</tr>
<tr>
<td>Exercise and sports</td>
<td>29</td>
</tr>
<tr>
<td>Regular visits to your doctor</td>
<td>30</td>
</tr>
<tr>
<td>Are there treatments available?</td>
<td>31</td>
</tr>
<tr>
<td>Other health problems associated with PKD</td>
<td>34</td>
</tr>
<tr>
<td>1. Liver cysts</td>
<td>34</td>
</tr>
<tr>
<td>2. Mitral valve prolapse (MVP)</td>
<td>35</td>
</tr>
<tr>
<td>3. Aneurysm</td>
<td>35</td>
</tr>
<tr>
<td>4. Hernias</td>
<td>36</td>
</tr>
<tr>
<td>5. Diverticulosis</td>
<td>36</td>
</tr>
<tr>
<td>Kidney failure</td>
<td>37</td>
</tr>
<tr>
<td>Dialysis</td>
<td>38</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>38</td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
<td>39</td>
</tr>
<tr>
<td>How will I choose the dialysis type for me?</td>
<td>39</td>
</tr>
<tr>
<td>Transplant</td>
<td>40</td>
</tr>
<tr>
<td>Transplant evaluation</td>
<td>40</td>
</tr>
<tr>
<td>How do I get a transplant?</td>
<td>41</td>
</tr>
<tr>
<td>Living donation</td>
<td>41</td>
</tr>
<tr>
<td>Deceased donation</td>
<td>43</td>
</tr>
<tr>
<td>Will my kidneys be removed before or after I have a transplant?</td>
<td>45</td>
</tr>
<tr>
<td>Does everyone with PKD eventually need dialysis or a transplant?</td>
<td>45</td>
</tr>
<tr>
<td>How are the costs associated with dialysis and transplant covered?</td>
<td>46</td>
</tr>
<tr>
<td>PKD and Children</td>
<td>47</td>
</tr>
<tr>
<td>Can I safely have children if I have PKD?</td>
<td>47</td>
</tr>
<tr>
<td>ADPKD and children</td>
<td>47</td>
</tr>
<tr>
<td>ARPKD and children</td>
<td>49</td>
</tr>
<tr>
<td>Resources</td>
<td>52</td>
</tr>
<tr>
<td>Glossary</td>
<td>54</td>
</tr>
<tr>
<td>Notes</td>
<td>60</td>
</tr>
</tbody>
</table>
INTRODUCTION

The purpose of this handbook is to provide information about autosomal dominant polycystic kidney disease (ADPKD). It will be useful to those who have the disease, those who are at risk due to an affected parent as well as invested family members and friends. It is not intended for those affected by autosomal recessive polycystic kidney disease (ARPKD). An ARPKD patient handbook is available at pkdcure.org. From here forward, ADPKD will be referred to simply as PKD.
PKD is a genetic disease (passed from an affected parent to their child) causing uncontrolled growth of cysts in the kidney. A normal kidney is the size of a human fist and weighs about a third of a pound. PKD kidneys can be much larger and weigh many pounds. The number of cysts can range from just a few to many. The size of the cysts can range from a pinhead to as large as a grapefruit.

Although the primary sign of PKD is cysts in the kidneys, there are other symptoms that can occur in various areas of the body. See Table 1 on next page for a list of common signs and symptoms of PKD.

Approximately 10 percent of people diagnosed with PKD have no family history. This means PKD has developed due to a spontaneous (new) mutation. Once a person has PKD, even through a spontaneous mutation, they have a 50 percent chance of passing it on to each of their children. See the genetics section on page 16 for more information.

**How common is PKD?**

PKD occurs in approximately 1 in 500 to 1 in 2000 live births affecting more than 600,000 Americans and 14.2 million people worldwide. It affects all racial and ethnic groups equally.

**How will I feel if I have PKD?**

Early in the disease, there are generally no symptoms. In fact, many people are never diagnosed with PKD because they have few or no symptoms. Often the first sign of PKD is high blood pressure, blood in the urine or a feeling of heaviness or pain in the back or abdomen. Sometimes the first sign may be a urinary tract infection or kidney stones.

**How do I find out if I have PKD?**

A physician is alerted to the possibility of PKD in three different settings:

- Family history of PKD
- Signs and symptoms that commonly occur in PKD
- Renal cysts are found in imaging tests

A positive family history is known in about 75 percent of patients with PKD. This is helpful to identify other at-risk family members. In general, the signs and symptoms of PKD are not specific enough to for your doctor to make the diagnosis. For example: PKD symptoms like back pain and/or high blood pressure are common in patients both with and without PKD and are not enough to make a definitive diagnosis.

**TIP**

Definitions for words in *bold italic teal* can be found in the Glossary (page 54).
Currently, there are three main tests that are used to screen for PKD:

1. Ultrasound
2. Computed tomography (CT)
3. Magnetic resonance imaging (MRI)

**Ultrasound** is the most common and least costly screening method for PKD. There are accepted standards for ultrasound testing to determine if you have PKD. These standards include the number of cysts visible, age, and family history.

**CT** and **MRI** scans are more sensitive than ultrasound for detecting small cysts. CT scans, however, involve radiation or may also require iodinated contrast dye, which can be toxic to the kidneys. CT scans or MRIs may also be used to look at complications of PKD such as bleeding or infection of a cyst, cyst rupture or kidney stones. A special type of PRI called a volumetric MRI is considered the best test to measure kidney volumes. Total kidney volume helps predict future loss of kidney function.

**DNA testing** is available for PKD. There are two types of DNA tests: **gene linkage testing** and **direct mutation analysis/DNA sequencing**.

DNA linkage can determine if you have PKD with a 99 percent probability in those with family history. Linkage testing is not a direct analysis of the DNA sequence of the PKD1 and PKD2 genes (more information on PKD genes starting on page 16). Instead, it relies on the identification of certain “markers” in the DNA of several members of a family in which PKD has been diagnosed. For linkage analysis, blood samples must be obtained from the person being considered for linkage testing.

**Possible PKD-related complications**

**POSSIBLE KIDNEY-RELATED PROBLEMS**

- Rupture, bleeding or infection of kidney cysts
- Frequent urination
- Kidney stones
- Hypertension (high blood pressure)
- Back and/or side (flank) pain
- Blood in the urine
- Frequent urinary tract infection
- Kidney failure

**POSSIBLE NON-KIDNEY-RELATED COMPLICATIONS**

**Cardiovascular**

- Mitral valve prolapse (floppy valve)
- Brain aneurysms: local bulging of the wall of blood vessels in the brain
- Aortic aneurysm: local bulging of the wall of the aorta
- Left ventricular hypertrophy: thickening of the heart muscle
- Loss of heart function (decreased ejection fraction)

**Gastrointestinal**

- Liver cysts with severe liver enlargement in a minority of patients (mostly female)
- Pancreatic cysts
- Diverticula (outpouchings or weakened areas) in the colon
- Diverticulitis (infection of the outpouchings) of the colon

**Other**

- Cysts in other organs such as seminal vesicles or epididymis (occurs in about 40 percent of males, can cause infertility in rare cases)
- Hernias of the abdomen
- Splenic cysts

Table 1
tested as well as several (typically three or more) family members including those affected and unaffected by PKD. A detailed family history is also required. The results are typically reported to all family members that provided blood samples for the analysis.

In contrast, direct DNA sequencing requires only a single sample from you (the person being tested). This method is a direct analysis of the DNA sequences of the PKD1 and PKD2 genes. It is private, and the results are only reported to you and your doctor.

Using very specialized scientific equipment, each of the nearly 17,000 “bases” of DNA are analyzed and the entire sequence is thus determined.

This method is capable of identifying those changes in the sequence that cause PKD. It may be your only option if family members are unavailable or unwilling to participate in a linkage study. Either method could be costly and should not be done without genetic counseling.

Health, life and disability insurance coverage vary between countries and may influence your decision to have genetic testing. In the United States, the Affordable Care Act has guaranteed health insurance for all regardless of any preexisting conditions. This does not guarantee life or disability coverage.

Genetic testing for a diagnosis of PKD should be carefully considered and discussed with your doctor.

Should I be tested?

It is an important and impactful decision. Things to consider before being tested:

▸ What will I do with the information once I have it?
▸ Will it prevent me from obtaining medical or life insurance?
▸ Am I better off knowing or not knowing?
▸ Can I financially afford the test?

Some people choose to remain undiagnosed but live a healthy lifestyle, eating well and monitoring their own blood pressure. They see the doctor often to monitor kidney function. If or when they have symptoms, they can revisit the decision to be tested.

Our understanding of PKD is progressing every year. Early diagnosis may benefit from early therapies and could also mean you are eligible to participate in clinical studies.

All these factors and more must be considered before making a decision.
Typically, each of us is born with two kidneys. They are located in the back of the body on each side of the spine, tucked under the rib cage (Figure 1). Each kidney is about five inches long (12 cm), three inches wide (8 cm), two inches thick (5 cm) and weigh 10 to 12 ounces (280 to 340 grams) each. Both kidneys become affected by PKD. The number of cysts detectable by imaging tests increases with age. Some have just a few cysts, while others develop too many to count. The size of individual cysts also increases with age and may range from that of a pinhead to a grapefruit. On average, your total kidney volume (TKV) as measured by MRI will increase by about 5 percent per year despite your kidney function remaining within the normal range for the first several decades. Recent studies have shown that TKV expansion to 1000 to 1500 mL (normal TKV: 250–350 mL) is associated with a significant risk for a future decline in kidney function. Thus, TKV is being used as a disease outcome measure in clinical trials of novel drug treatments for PKD.

Your kidney is a filter

Each of your kidneys contains about one million tiny filters called nephrons. The nephrons are made of a tuft of thin blood vessels in a spherical structure called the glomerulus, which is connected to a series of tubules (Figure 1). Almost a quarter of the blood your heart pumps every second passes through the nephrons. Red blood cells, white blood cells, and large substances like proteins do not normally pass through, staying inside the glomerular blood vessels instead. The 47 gallons (180 liters) of fluid that passes through the filters of your kidneys each day is made up of water, electrolytes (sodium, potassium, calcium, and phosphorus) and other small substances. Most of the fluid that passes through the glomerulus is modified and reabsorbed during transit through the tubules of the nephron. This leaves one quarter to one half gallon (1 to 2 liters) as urine each day. The process of filtering and reclaiming fluid along the nephron enables normal kidneys to perfectly maintain your body’s fluid composition with electrolytes and blood pH regulated within a specific range. Your kidneys also filter and excrete waste products generated from your diet and body metabolism each day.

Waste products cleared by the kidneys

Blood Urea Nitrogen (BUN) and creatinine are two waste products removed by the kidneys. Creatinine is removed so efficiently that your doctor can calculate approximately how much actual kidney function you have with a blood test for creatinine compared to a 24-hour urine collection, height and weight. The 24-hour test is called creatinine clearance and is
approximately equal to the true glomerular filtration rate (GFR) of your kidneys which is only measured precisely for research purposes. Your creatinine clearance tells your doctor the approximate percentage kidney function you have.

Hormones and your kidneys

Your kidneys also make several essential hormones and enzymes. One of these is renin, an enzyme that facilitates the production of other hormones such as angiotensin (helps regulate blood pressure) and aldosterone (aids in the body’s handling of salt and potassium). Another hormone made in the kidneys is erythropoietin, commonly known as EPO. This hormone tells the bone marrow to make red blood cells. If your kidneys are surgically removed or if they fail because of kidney disease, EPO is no longer produced and blood transfusions must be given every five or six weeks. The EPO gene was discovered almost three decades ago. A genetically engineered form of EPO is now available, allowing kidney patients to avoid the need for blood transfusions.
The kidneys also convert vitamin D to its active form, which helps the body absorb calcium from the diet. In this way, the kidneys help control the blood calcium and phosphate levels, which is important for bone health.

**Cysts in the kidney**

In the kidney, a cyst begins as an outpouching of the nephron — similar to a blister — and can occur anywhere along the length of the nephron. The fluid inside the cysts often reflects the area in the nephron that the cyst began.

Approximately 70 percent of cysts detach from the nephron once they reach ¼ inch (2 mm) in diameter. Over time, the cysts enlarge and can become filled with clear fluid or blood. Cysts can also form in other organs, with the liver being the most common site. Liver cysts are derived from the bile ducts or tubules.
What causes cysts to form?

Mutations of the PKD1 or PKD2 gene reduce the normal level of polycystins, which regulate many important tubular cell functions. Recent research has highlighted a central defect in PKD related to dysregulation of calcium levels and a signaling molecule called cyclic AMP (cAMP) within the cells that form tubules in the kidneys and other target organs. These abnormalities in turn can lead to cyst formation through these important mechanisms [Figure 3]:

- **CELL PROLIFERATION (GROWTH):** the cells lining a cyst reproduce themselves more than normal kidney cells do, making them grow in size. This process, essential to growth and replacement of the old cells, leads to increased cyst growth in PKD.
- **FLUID SECRETION:** these abnormally growing cells secrete fluid, which expands the cyst. Without fluid secretion, a cyst would collapse like a deflated balloon.

Two basic processes simultaneously occur in the formation of cysts:

**Cell proliferation**
One cell divides into two cells. Then these two cells divide into four cells…

**Fluid secretion**
Sodium, chloride and water move into cyst.
How do cysts cause problems?

In general, cysts cause problems because of their size and the space they occupy [Figure 4]. Many of the symptoms you may have are dependent on how large your kidneys are, as detailed below:

- Kidneys more than 6 inches (15 cm) are more likely to cause pain than smaller kidneys
- Patients with bigger kidneys are more likely to experience high blood pressure than those with smaller kidneys
- Patients with bigger kidneys are more likely to have bleeding into their urine than those with smaller kidneys
- Patients with bigger kidneys are more likely to experience more rapid loss of renal function than those with smaller kidneys

![Kidney Disease Progression in ADPKD](image-url)

*Figure 4* Adapted from Grantham 2006 by Otsuka
**Blood tests**

*Creatinine* is a waste product of muscle. The level of creatinine in your blood is a measure of kidney function. After creatinine leaves the muscles, it enters into the blood, then is filtered by the kidneys and ends up in the urine. There is always some creatinine in your blood and urine. When you lose kidney function, your kidneys do not clear creatinine from the blood as efficiently. This causes an increase in creatinine in the blood, which can be measured by a blood test. Creatinine level is the preferred measure of kidney function. There are equations that can be used to estimate kidney function or glomerular filtration rate (called estimated GFR or eGFR) from serum creatinine, age and race.

Normal blood creatinine is generally 0.6 to 1.4 mg/dl. If a person’s blood creatinine goes up from 1.0 to 2.0 mg/dl, he or she has lost approximately 50 percent of kidney function.

*Blood urea nitrogen (BUN)* is another measure of kidney function. Urea nitrogen is the waste product of dietary protein. If your kidney function is decreased, the urea nitrogen builds up in the blood. Many factors—including diet, protein intake, heart function and fluid status—can affect your BUN, making it less preferred than creatinine for determining kidney function.

The normal range for BUN is 6 to 15 mg/dl.

*Liver function tests* (AST, ALT, TBili) are also routinely measured blood tests. These tests are almost always normal even if there are cysts in the liver. If your liver function tests are not in the normal range, your physician should look for a cause other than PKD.

**Urine tests**

*White blood cells (WBC)* in urine are normally present only in small numbers; some PKD patients do pass a few more. However, large numbers of WBCs in the urine suggest a *urinary tract infection*. If this happens, your doctor will culture your urine to determine if and what types of bacteria are present and from those results plan a course of action.

*Red blood cells (RBC)* in the urine is also called *hematuria*. Only a few RBCs are normally found in the urine. When the number increases but the urine is still a normal color, this is called microscopic hematuria. Sometimes with an episode of cyst bleeding, there are so many RBCs that the urine may be pink, red or brown. About 50 percent of PKD patients will experience this at some point.

Protein in the urine is also called *proteinuria*. Normal urine has protein, but only in small amounts. About one-third of those with PKD pass high amounts of protein into the urine, but it is usually less than a gram over a period of 24 hours. If protein loss is greater than one gram in 24 hours, there may be another problem occurring in the kidneys along with PKD.

*24-hour urine collection* test is done in combination with the blood creatinine test to determine kidney function, called *creatinine clearance*, which is an approximation of the *glomerular filtration rate (GFR)*.
Imaging tests

Imaging tests are those used to see the details of organs or blood vessels in the body.

**Ultrasound** is a test done with sound waves and does not require the use of radiation or contrast dye to be injected. Because it is safe and accurate, ultrasound is the most common imaging test done to screen for PKD and can be done safely in pregnant women.

**Echocardiogram** is an ultrasound of the heart. One of the uses of an echocardiogram is to image the valves of the heart. Your physician may order this test if he or she suspects you have mitral valve prolapse (MVP) (see page 16 for more information on MVP).

**Computed Tomography (CT Scan)** is a sophisticated form of an X-ray. CT scans use radiation and may use contrast dye to visualize the organ or blood vessels being studied. Contrast dye can sometimes cause allergic reactions or kidney damage in patients with moderate to advanced kidney failure. This imaging technique is very helpful to evaluate the complications of PKD, such as bleeding into a cyst or kidneys stones. *High-resolution CT scans*, under certain circumstances, may be used to visualize the blood vessels in the brain. We no longer use this method to routinely screen for aneurysms.

**Magnetic Resonance Imaging (MRI)** takes pictures of the body using a magnet that puts a certain spin on atoms that exist in a person's body. It does not require radiation. A special dye called gadolinium may be used in some instances to improve visualization. Patients with moderate to advanced kidney failure may retain this dye in the body, which can cause a rare but serious complication called nephrogenic systemic fibrosis (NSF). If you have kidney failure and are asked to undergo an MRI with gadolinium, make sure you discuss this concern with your doctor. Cysts are easily visualized with MRI and appear in better detail than ultrasound. MRIs allow for accurate determination of kidney volume.

**Magnetic Resonance Angiography (MRA)** is a type of MRI that is used to visualize the blood vessels in the brain to screen for aneurysms. This is similar to an MRI scan, and can be performed without contrast dyes or radiation. MRA is the recommended method for aneurysm screening.

**Angiograms** are procedures in which contrast dye is injected into the blood vessels to clearly visualize the blood vessel walls. An angiogram is usually recommended when an aneurysm is suspected. Angiograms may also be performed to look for blockages in heart vessels.
PKD GENETICS

How does disease inheritance work?

Your body is composed of about 40 trillion cells, almost all of which have two basic parts: the **nucleus** and the **cytoplasm** (Figure 5). The nucleus is the control and operational center of the cell while the cytoplasm is vital to proper cell function. Each of your cells contains a genetic blueprint inherited from your parents that determines what your cells do.

Each cell’s nucleus contains tiny threads called **chromosomes**. All the necessary information required to direct the formation and function of a human being is contained in 23 pairs of chromosomes. In turn, each chromosome contains hundreds to more than a thousand **genes** — the basic units of heredity. Genes are pieces of DNA so small they are barely visible, even under a powerful **electron microscope**.

The building blocks of genes are chemical substances called **nucleotides**. There are four nucleotides: adenosine, thymidine, cytosine, and guanine, commonly expressed as A, T, C, and G. Ultimately, the genetic code that programs our cells is made by these four nucleotides. A sequence of three nucleotides is called a codon. Each gene is made up of hundreds to thousands of codons, which form the template for a messenger **RNA (mRNA)**. Each mRNA in turn provides the instruction for the cellular machinery to make a protein.

Each protein has a unique function within a cell by providing structural support, regulating metabolic processes, or coordinating communication between cells. In a genetic disease such as PKD, there is a mistake or mutation within a gene, which can lead to an altered protein with abnormal function or a decreased level of a normal protein.

A single nucleotide change is enough to cause the gene to code for an abnormal protein and cause a disease.

The goal in treating a genetically inherited disease is to find out how the abnormal protein alters the normal cell function and to partially or fully restore the aberrant function using specific drug(s). In the future, it may be possible to replace the defective gene.

PKD research has a two-pronged approach:

1. **DISCOVERY RESEARCH** focuses on understanding certain cell functions and pathways and their implications for the whole organism.

2. **DRUG DEVELOPMENT** focuses on applying the knowledge gained in discovery research to develop medicine or biomedical technology that will alter or correct the anomalies caused by the PKD genes.
The kidney, like the rest of the body, is made up of millions of cells. Each cell has a **nucleus** which houses the genetic material, called **DNA**. Most of the time DNA is wound tightly into structures called **chromosomes**. There are 23 pairs of chromosomes in each cell nucleus with half inherited from the mother and half from the father. One pair, X and Y, are referred to as the sex chromosomes because they contain genetic information specifically for “maleness” or “femaleness.”

**DNA** is described as a “double helix,” since its structure is like a ladder twisted length-wise over and over. This incredibly long and thin molecule contains the genetic code for what makes you, “you.” The “rungs” of the “ladder” are made from two of four **nucleotides**, and the sequence of these nucleotides create the “recipe” for a cell product or function, much like how Morse code transmits language.

**A gene** is a length of **DNA** which codes for a single cell product or function. For instance, the kidney produced protein **Renin**, which helps regulate blood pressure, is made from the recipe contained in its gene, comprised of 20,000 pairs of nucleotides.

**A mutation** occurs when the wrong nucleotides occur in a gene. This changes the recipe for the product of that gene, leading to cell malfunction. About 80-85% of people with ADPKD have a mutation in the ADPKD gene located on chromosome 16, called **ADPKD1**. The remaining ADPKD population have a mutation in the ADPKD gene located on chromosome 4, called **ADPKD2** (See above). These genes code for different proteins that work together.

---

**Figure 5**

---

**Note:** The color of the chromosomes as shown is false, and is due to the staining process used to make the chromosomes more visible.
What do we know about PKD genes?

PKD is caused by mutations (unintended change or typo) in two genes. Mutations of the first gene, PKD1, account for about 85 percent of patients affected by PKD, while mutations of the second gene, PKD2, account for the remaining patients. There are no other PKD genes that have been identified to date. The PKD1 and PKD2 genes encode the proteins polycystin-1 and polycystin-2, respectively. These two proteins interact to regulate cells in the kidneys and liver to maintain their orientation to form tubular structures as well as their growth and fluid secretion function. Mutations of the PKD1 or PKD2 gene leads to a wide array of cellular abnormalities associated with normal polycystin function and ultimately result in PKD.

There is a marked difference in kidney disease severity associated with mutations that inactivate the PKD1 compared to the PKD2 gene. Specifically, patients with inactivating PKD1 mutations have bigger kidneys, more kidney-related complications, and require dialysis at an earlier age compared to those with PKD2 mutations (55 versus 75 years, respectively). More recent studies have also identified a subset of PKD1 patients with milder kidney disease in which their mutations do not seem to completely inactivate polycystin-1 function; this is called a non-truncating PKD1 mutation.

Determining the specific gene mutation you have requires genetic testing. This type of testing is not typically covered by health insurance and could be costly (several thousand dollars). If you or someone you know chooses to explore this option, Athena Diagnostics (athenadiagnostics.com) was the first lab to begin PKD genetic testing and it continues to do so today.

<table>
<thead>
<tr>
<th>Fertilization scenario 1</th>
<th>Has PKD</th>
<th>Fertilization scenario 2</th>
<th>Has PKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Half of the ova contain the defective gene...</td>
<td>Ova half do not.</td>
<td>Half of the ova contain the defective gene...</td>
<td>Ova half do not.</td>
</tr>
<tr>
<td>91</td>
<td>91+σ1</td>
<td>91+σ2</td>
<td>91+σ2</td>
</tr>
<tr>
<td>92</td>
<td>92+σ1</td>
<td>92+σ2</td>
<td>92+σ2</td>
</tr>
<tr>
<td>Fertilization scenario 3</td>
<td>Does not have PKD</td>
<td>Fertilization scenario 4</td>
<td>Does not have PKD</td>
</tr>
</tbody>
</table>

Fertilization is a random event. Since none of the male sperm carry the defective gene, but half of the female ova do, there’s always a 50/50 chance that any offspring will have the defective gene.

Figure 6

*One copy of chromosome 4 has the ADPKD2 mutation*
How is PKD inherited?

Most cells in our body inherit one set of 23 chromosomes from each parent to make a total of 46 chromosomes (Figure 6). Twenty-two pairs are called *autosomes*; the remaining pair are called the *sex chromosomes* since they contain genes that determine gender. The only exception to the above are the *germ cells* (eggs in females and sperms in males), each of which only has a set of 23 chromosomes that are inherited from our parents. Upon fertilization of an egg by a sperm, the full complement of 46 chromosomes is restored. The fertilized egg develops into an embryo and eventually a fully grown being.

The term “*autosomal dominant*” in ADPKD refers to two important features of the disease. First, because the disease genes reside on an *autosome* (i.e., PKD1 on chromosome 16 and PKD2 on chromosome 4), both male and female at-risk patients have an equal chance of inheriting PKD. This means that the possibility of transmitting PKD from an affected parent to a child is 1 in 2, or 50 percent (like flipping a coin) when a large number of families are studied. However, the number of affected children within a single family is entirely due to chance and may or may not be 50 percent. Second, the disease is dominant because inheritance of one copy of the mutated *PKD1* or *PKD2* gene from one parent is sufficient to cause disease. By contrast, the inheritance of a copy of a mutated gene from both parents is required for a *recessive* disease.

---

**Autosomal dominant polycystic kidney disease inheritance**

![Figure 7](image-url)

- Unaffected
- Affected

*Figure 7*
Four to 10 percent of patients with PKD may have “de novo” disease due to a *spontaneous mutation*. Typically these patients do not have a family history of PKD. Their disease is due to a spontaneous mutation of the *PKD1* or *PKD2* gene in one of the germ cells (i.e., egg or sperm) of one of their parents that then gets passed on to them. Individuals with “spontaneous mutations” thus become the founders of a bloodline, which is continued into the next generation with a 50 percent chance of disease transmission. Most of your body’s cells carry one normal and one mutated copy of the PKD gene. However, when sperms or eggs are formed in that person, only one of the two copies of a PKD gene is passed on, typically with equal chance. Only the sperms or eggs that carry a mutated PKD gene can pass on the disease. Therefore, the chance of disease transmission to your children is typically 50 percent.

Carrying two copies of the same PKD gene (two *PKD1* or two *PKD2*) is generally not compatible with life, if the mutations are truncating on inactivating.

**If I have four children, does this mean that two of my children will have PKD and two will not?**

No, this is not necessarily the case. The risk of having a child who inherits the PKD gene is always 50 percent with each individual pregnancy, no matter how many children a couple has. It’s like the flip of a coin — there is always a 50 percent chance of getting heads and a 50 percent chance of getting tails. In some families, all of the children are affected, while in other families, none are. Many families with multiple children will have both affected and unaffected children.

**Will a person with a mutation for PKD always have the disease?**

Yes. The genes for PKD are dominant, which means that inheriting only one mutated copy of the *PKD1* or *PKD2* gene from an affected parent is sufficient to cause the disease. There is no carrier state with a dominant disease, and it does not skip a generation. This means that the disease will eventually manifest as you get older and that all generations have the potential to be affected. If you have a mutation, at some point in your life at least some of the symptoms of the disease will probably occur, although they could be very mild. When an at-risk individual does not have a mutation for PKD, he/she is not affected and the disease cannot be passed to the next generation.

This does not mean that everyone who gets the PKD gene will have the same signs or symptoms or the same course of the disease. There is a wide spectrum of severity within PKD. At one end are children who are diagnosed before birth or in the first year of life with cysts or big kidneys, at the other end are people who have few symptoms, even when they are much older. It is important to note that some individuals (especially those with a *PKD2* or non-inactivating *PKD1* mutation) are more likely to live a normal life span and die of other causes before there is a need for dialysis or transplantation. A majority of patients with PKD will fall in the middle and at some point in their life will have some signs or symptoms associated with PKD.

**Will everyone with a mutation in the same family have the same type of PKD?**

Yes, all affected PKD patients with the same mutation in a family will have the same type of PKD. However, the signs, symptoms, and course of the disease are often different. The most dramatic example of this occurs in families with children who are diagnosed before birth or in the first year of life. These children have symptoms long before their parents. Sometimes the parent may not even be aware they have PKD until after their child is diagnosed. Significant kidney disease variability within PKD families suggest other genetic and environmental factors can modify the severity of this disease.
High blood pressure (hypertension)

**Blood pressure** is a measurement of the force of the blood as it flows through the body. The pressure depends on the amount of blood and fluid in the body, the amount of blood the heart pumps each second (cardiac output), and the degree in which blood vessels are constricted or enlarged. Consider the force it takes to get water through a garden hose. The pressure depends on how much water is going through the faucet and how narrow the hose is.

Blood pressure measurements have two parts, recorded as millimeters of mercury (mm Hg) — for example: 120/80 mm/Hg (read as 120-over-80). The top/first number is the **systolic blood pressure**, which measures the pressure when the heart contracts (pumps). The bottom/second number is the **diastolic pressure**, which is the measurement of the pressure when the heart is relaxing between beats.

**High blood pressure**, or **hypertension**, affects about 60–70% of PKD patients and begins early in the course of the disease. Half of PKD patients who have normal kidney function have hypertension. It is more common in men than in women. Twenty to 30 percent of children with PKD also have hypertension. Many times, the increase in blood pressure is the first sign of PKD. Patients with high blood pressure generally have larger cystic kidneys than those with normal blood pressure.

High blood pressure needs to be treated aggressively. If not treated, hypertension causes further damage to the kidneys, enlarges and thickens the heart muscle, and increases the risk for strokes and other cardiovascular events.
Hypertension is caused by either an increase in cardiac output or a constriction of the blood vessels. In PKD, enlarging cysts may press on blood vessels in the kidney, which increases activity of the renin-angiotensin-aldosterone system. This leads to the release of hormones, which increases the blood pressure.

Renin is an enzyme produced in the kidneys. It acts on angiotensinogen, a substance in the blood that forms a hormone called angiotensin. Angiotensin is a powerful constrictor of blood vessels; it also stimulates the production of aldosterone, which causes the body to retain salt and lose potassium.

In ordinary circumstances, the kidneys make renin when blood pressure is low and the kidneys sense they need more blood flow. This is a protective mechanism to ensure adequate blood pressure in the rest of the body. In PKD, cysts can press on blood vessels in the kidney, resulting in decreased blood flow to some parts of the kidney. Sensors in the nephron react as though the blood pressure in the kidney was low, triggering the secretion of renin, which in turn generates angiotensin, constricting the blood vessels, and causing high blood pressure.

There is a relationship between poor blood pressure control and progressive loss of kidney function in PKD. Even if you do not have hypertension, you should have your own blood pressure cuff to monitor and log your blood pressure regularly. This will give your doctor a better picture of your blood pressure over time.

Hypertension in PKD is often treated by a group of drugs called angiotensin converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs). These two classes of drugs are usually the first drugs of choice because of the role of angiotensin in high blood pressure in PKD. In general, both types of drugs are safe and effective; however, in some patients with decreased kidney function, these drugs can make kidney function worse and can raise potassium levels.

Regardless of what kind of blood pressure medication is used, the most important thing is to have your blood pressure at or near the normal range of about 110/70 to 130/80. There are many choices of very good medications to treat high blood pressure so you should work with your doctor to find the right one(s) for you. Remember, a blood pressure medicine only works if you take it, so you need to have a regular, set time to take your medicine every day so you don’t forget.

Although medication is important in treating blood pressure, non-drug methods can also help to lower blood pressure. Living a healthy lifestyle including weight loss, exercise, and a low-salt diet are all an important part of staying as healthy as possible.

Kidney pain

Abdominal, side (flank) or back pain in patients with PKD can be severe, signaling a sudden problem like bleeding into a cyst, cyst infection or passage of a kidney stone. Intense pain in this setting can also be due to non-kidney related causes such as vertebral disc herniation, ruptured liver cyst, passage of gallstones, or diverticulitis.

HALT-PKD study

In fall of 2014, a team of researchers announced the results of a national study on PKD and hypertension. The results concluded that:

▸ Rigorous blood pressure control, early in the disease, could slow cyst growth in ADPKD
▸ Only one type of medication is necessary to prevent hypertension
Chronic pain is one of the most common problems for patients with PKD. The pain is usually in the back or the side and occasionally in the stomach. It can be intermittent and mild requiring only occasional pain medicine such as acetaminophen (Tylenol). Some patients also benefit from nerve blocks to control pain. However, in a small number of patients with severe PKD, the pain can be constant and quite severe. For these patients, surgery may be needed.

If you have a few very big cysts causing the pain, they can be aspirated and sclerosed with chemicals that are injected into cysts. Sclerosis is done using an ultrasound or CAT scan to guide your doctor to insert a needle into the cyst(s), drain the fluid, and then coat the cyst wall with a sclerosing substance to remove the cyst’s lining cells. If you have severe pain due to a greatly enlarged polycystic kidney, surgical approaches may also be considered. For example, laproscopic cyst decortication or surgical nephrectomy may be possible, especially if you are already on dialysis/end stage renal disease.

Pain is a very subjective feeling. Only the person feeling the pain can measure how bad it is. It is important to remember that pain frequency and tolerance vary greatly among individuals. Pain tolerance appears to be influenced by a person’s cultural background, expectations, behaviors, physical and emotional health. For this reason, pain clinics that utilize biofeedback and support groups can be very helpful in managing your pain. Pain clinics are sometimes a division of the anesthesiology department of a surgical hospital. To find a pain clinic, talk with your doctor or nephrologist to be directed to one that can help you with your specific PKD pain needs.

Blood in the urine

More than half of patients with PKD will have blood in their urine (hematuria) at some point. The urine may look pink, red or brown. Passing small amounts of red blood cells in the urine that can only be seen under a microscope may also occur. This is called microscopic hematuria.

Hematuria is more common in an individual with large kidneys and high blood pressure. It is thought that the rupture of cysts or of the small blood vessels around cysts is the cause. Other causes could include kidney or bladder infection and kidney stones.

Blood in the urine can last for less than a day or may go on for days. Notify your doctor as soon as possible if you see blood in the urine. Bed rest, increased fluid intake, and acetaminophen (if there is pain) are the usual treatments. Avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin or ibuprofen as they may prolong the bleeding and could damage your kidneys. If the blood is going directly into a cyst, you may not have blood in the urine but pain could be severe.

Urinary tract infection

A urinary tract infection, commonly called a UTI, is an infection caused by bacteria in the bladder, kidneys or cysts. Other names used for UTIs are cystitis for bladder infection and pyelonephritis when the infection is in the kidney.

The infection usually starts in the bladder but, if not treated, can progress up the ureters (the tubes from the kidneys to the bladder) and into the kidneys. Although both men and women can have UTIs, they are far more common in women because they have a shorter urethra (the tube that goes from the bladder to the outside).

UTIs are quite common in the general population but may be more frequent in those with
PKD. There is an association between frequent UTIs and worsening kidney function. Both males and females with PKD are more likely to have an infection after a Foley catheter is placed in the bladder.

The most common symptom of a UTI, particularly if the infection is in the bladder, is pain or burning with urination and/or an urgent need to urinate even though only a small amount of urine is passed. When the infection is in the kidney or in a cyst, there may be fever, chills, back or flank pain.

You should notify your doctor if any of these symptoms occur so treatment can be started. Usually a urinalysis is done. This includes providing a urine sample to be screened to determine the type of bacteria that is causing the infection so the appropriate antibiotic can be prescribed.

Women who have frequent bladder infections may decrease or eliminate the rate of recurrence by:

- Wiping from front to back after urinating or a bowel movement — this prevents dragging bacteria from the anus and vagina to the urethral opening
- Not taking baths
- Drinking fluid prior to intercourse and urinating afterward — this can help flush out any bacteria that may have entered the urethra

For those who have frequent UTIs, antibiotics may be prescribed to prevent recurring infections.

**Kidney stones**

*Kidney stones* occur in about 20 to 30 percent of patients with PKD as compared to one to two percent in the general population. One reason kidney stones are more common may be due to cysts blocking the tubules (filtering part of the kidney; see page 9), preventing normal drainage. When the urine stays in one area longer than it should, crystals can form and cause kidney stones. *Uric acid* and *calcium oxalate* are the two most common types of crystals that lead to stones. Stones may also form in some PKD patients because of a decrease in *urine citrate*, a substance that prevents formation of kidney stones.

The symptoms of kidney stones include severe pain in the back, side or into the groin. Kidney stones are treated the same way in PKD patients as in non-PKD patients. Smaller stones can be passed with the urine; often there is blood in the urine as a stone is moving. In the case of bigger stones that cannot be passed, surgical treatment may be required. If you have recurring stones, your doctor may order a 24-hour urine collection to analyze the composition of your urine and determine treatment based on your individual risk factors.

**WARNING**

Avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen or Naprosyn for pain.
STAGES OF CHRONIC KIDNEY DISEASE

If you have kidney damage and/or a decrease in kidney function for three or more months, it is called chronic kidney disease (CKD). There are five stages of CKD, with progressive symptoms.

**STAGE 1** Includes signs of mild kidney disease, with a normal GFR showing 90 percent or higher kidney function.

**STAGE 2** Includes signs of mild kidney disease with a GFR showing 60 – 89 percent kidney function.

**STAGE 3** Includes signs of moderate kidney disease and a GFR showing 30 – 59 percent kidney function (sometimes divided into 3A (60 – 45) and 3B (30 – 45). Patients with 3B are at higher risk of progression.

**STAGE 4** Includes signs of severe kidney disease and GFR showing 15 – 29 percent kidney function.

**STAGE 5** Includes signs of severe kidney disease and kidney failure, with a GFR showing less than 15 percent kidney function.

The problems below can occur in all stages:

- Blood in urine
- UTIs
- Kidney stones
- Aneurysms in brain

Treatment options to discuss with your doctor:

- Limit protein intake
- Limit salt intake
- Consider hypertension medication (see box on HALT-PKD study on page 22)
- Discuss use of tolvaptan if you are at high risk of loss of kidney function

**CKD in PKD**

The stages of CKD in PKD have specific indicators including:

**PKD stages 1 – 2**

- Few physical symptoms
- Labs may show slightly elevated creatinine
PKD stages 3–4
May have no physical symptoms or may have:
▶ Fatigue
▶ Back pain
▶ Puffiness or swelling
▶ Loss of appetite
▶ Food may taste funny
▶ Hypertension
▶ Abdominal swelling

PKD stage 5
Physical symptoms include:
▶ Anemia
▶ Weak, tired, drowsy
▶ Headaches
▶ Confusion, difficulty concentrating
▶ Nausea, vomiting, decreased appetite
▶ Itching
▶ Muscle cramps
▶ Swelling and puffiness
▶ Shortness of breath
▶ Hypertension
▶ Change in skin color (grayish or yellowish)
▶ Women may experience changes in menstrual cycle
Diet

Currently no specific diet has been proven to make your polycystic kidneys better or keep them from getting worse. It is, however, ideal to eat a balanced and healthy diet to maintain optimal body conditions. A healthy body is able to fight infection better, and bounce back faster. Accumulation of waste products filtered by your kidneys will build up in your blood as kidney function declines. At the more advanced stages of kidney failure (i.e., GFR <30–40 percent or stage 3B CKD or higher), significant accumulation of these waste products in your blood can cause symptoms of kidney failure.

Should I stop eating protein?

Eating protein leads to the production of acid and urea, which must be cleared by the kidney. Studies from both animals and humans with chronic kidney failure have shown that eating large amounts of protein may accelerate the progressive decline of kidney function. However, the Modification in Diet in Renal Disease (MDRD) study done by the National Institutes of Health (NIH) looked at protein intake and kidney function. The results did not show any benefit of lowering protein intake in individuals with PKD. At this time, there is no convincing evidence to suggest protein restriction is beneficial. However, many consider it unwise to consume a very high protein diet, such as an Atkins or South Beach diet. Guidelines for appropriate protein intake change depending on the severity of the kidney disease. For more information, you should consult your doctor or a dietitian experienced with kidney disease (also known as a renal dietician) who ideally has knowledge of PKD.

Should I stop eating salt?

High blood pressure in PKD does not seem to be caused by salt intake. Regardless, excessive amounts of salt should be avoided and lowering dietary salt may help in blood pressure control. Lowering dietary salt intake may also slow the decline in renal function. Therefore, everyone with PKD should be on a low-salt diet.

Can I drink alcohol?

Light and/or occasional use of alcohol has not been shown to damage the kidneys or the liver. However, drinking three or more ounces of alcohol a day for many years has been associated with increases in blood pressure and can damage the liver.

Can I use tobacco?

Smoking increases the risk of heart disease and stroke and, when paired with hypertension, the risks are even greater. Smoking also increases the risk of cancer. Do not smoke if you have PKD.
Should I take extra vitamins to make sure I’m getting all the nutrients I need?

If you are maintaining a balanced and healthy diet, you typically will not need vitamin tablets. Vitamins are needed only in tiny amounts. Excess amounts of vitamins A, D and E can accumulate in your body and cause medical problems. Generally, if you feel you need vitamins, a one-a-day generic brand of vitamin is sufficient. Consult your doctor before taking vitamins of any kind. Because there is an increased incidence of calcium kidney stones in individuals with PKD, discuss taking calcium supplements with your doctor as they may increase the risk of kidney stones. Limiting calcium in the diet will not prevent kidney stones in non-PKD patients and the beneficial effects of appropriate dietary calcium intake on skeletal and cardiovascular systems are well established.

How much fluid should I drink each day?

A chemical called cyclic AMP (cAMP) has been shown to promote growth of polycystic kidneys. In your kidney, cAMP is produced in response to a hormone, vasopressin, which is produced by the brain in response to not having enough water. Thus, avoiding dehydration is thought to be prudent. In addition, generous water intake has the potential to suppress vasopressin production and decrease cAMP production in the kidney. Though there is no good data regarding this in humans with PKD, if kidney function is not impaired, water intake is typically safe. Therefore it seems reasonable to suggest intake of water with a goal of 2–3 quarts of urine output daily. Your urine should generally be pale in color. This will tend to suppress vasopressin production by the brain and cAMP production in the kidneys.

Finally, generous water intake helps maintain a dilute urine and decreases the risk of kidney stones, which are seen at increased frequency in PKD patients.

It is important to understand that the benefit or risk of high water intake have never been formally studied in PKD patients, and therefore results cannot be predicted or guaranteed. In addition, as kidney function deteriorates, generous water intake can be problematic and even dangerous. Thus, it is important to discuss appropriate water intake with your doctor.

Will caffeine damage my kidneys?

There is no direct evidence that caffeine will damage your polycystic kidneys. However, studies of PKD cells grown in a lab have shown that caffeine-like substances promoted cyst growth in PKD. At this time, it may be wise to limit caffeine intake to less than 200 to 250 mg (i.e., two to three cups of coffee) a day.

What about potassium?

Potassium is essential to all living cells and is important for muscle and nerve function in the body. It is found in most foods, including legumes, whole grains, fruits, green vegetables, potatoes, meats, milk and yogurt. Although potassium is vital to the body, and a high potassium diet may help reduce high blood pressure, it is not wise to take potassium supplements in pill or liquid form without consulting your doctor and/or your renal dietician, especially if your kidney function is reduced.
What about calcium and magnesium?

In non-PKD settings, a deficiency of calcium and magnesium has been associated with high blood pressure. Dietary calcium and magnesium are best provided by dairy products and are important in maintaining a normal mineral balance as part of healthy diet.

Essentials for a balanced and healthy diet

Given the current obesity epidemic that is prevalent in all developed countries, the following provides a simple conceptual framework for a balanced and healthy diet:

▸ **HIGH FIBER:** fresh vegetables and nuts

▸ **LOW CARBOHYDRATES:** minimize intake of bread and pasta

▸ **MODERATE PROTEIN:** moderation of red meats

▸ **HEALTHY FATS:** moderate intake may actually decrease hunger drive — choose healthy fats such as olive oil

▸ **TO AVOID:** processed food and sugary drinks with fructose syrup

▸ **MODERATE PORTIONS:** decrease food portion size if you are overweight

If you have moderate to advanced kidney failure, further modification of the above will be required and consultation with your doctor and a dietitian experienced with kidney disease is recommended.

DASH diet

Studies in high blood pressure patients without PKD have shown that the DASH diet (dietary approach to stopping hypertension), which consists of a good intake of fruits and vegetables combined with low-fat dairy, may lower blood pressure. A diet based on these guidelines could also be appropriate for PKD patients with good kidney function. Look in the resources section at the back of the book for web resources on the DASH diet. Talk to your doctor before significantly altering your diet.

Exercise and sports

Exercise is an important part of maintaining good, overall health. Regular exercise can decrease your blood pressure and stress as well as improve muscle strength, heart function and stamina. It can also enhance a sense of well-being. In general, you will do much better on dialysis and with a transplant if you are physically fit.

What kind of exercise is best?

There is no one best kind of exercise. The key is to find an activity that is comfortable or you and that you enjoy doing. Generally, PKD patients can do any activity they want unless they get blood in the urine or it causes back, flank or abdominal pain. The exercises that are least jarring to the kidneys include walking, swimming and biking.

Be sure to talk with your doctor before starting an exercise regimen, as he or she may have guidance about what will be most effective for you, or what to avoid. Remember to always keep well hydrated when exercising, and do your best to be active on a regular basis.

Are sports dangerous to my kidneys?

In general, most sports do not affect kidney function. However, PKD does present unique circumstances and so there are some issues that need to be considered. Given the unique nature of PKD, where kidneys are enlarged and cysts can rupture, there are some simple precautions to take.
Contact sports where the kidneys may be traumatized (flank/side or lower back impact) should either be avoided or protective pads should be worn. Examples of these types of sports include football, rugby, basketball, hockey, and particularly boxing or kickboxing. Horseback riding and cross-country biking are other sports with repetitive impact that could potentially cause issues for your kidneys. There is no evidence that these activities worsen renal function, but they can result in pain and/or blood appearing in the urine.

**Regular visits to your doctor**

**What kind of doctor should I see?**

In addition to your general practitioner (also called an internist), you should also see a doctor who specializes in kidneys. A **nephrologist** (kidney specialist) will be able to advise you best on how to care for your polycystic kidneys and the other related symptoms. Ideally you should see a nephrologist with experience treating PKD, but this may be difficult depending on where you live.

If you have more than one doctor, they should all be working together in a coordinated approach to your health care. This does not always happen so you must not be afraid to vocalize your concerns and ask your doctors to talk to each other, especially if you are getting conflicting advice from them. If you are being prescribed different medication by multiple doctors, keep track of this and be sure to tell each doctor about all of your prescriptions to ensure no adverse effects.

Find a doctor(s) you trust and with whom you work well. Don’t be afraid to “shop around” or visit with several different doctors until you find one you like and trust. Be involved in your own health care and become your own expert by gathering as much information as possible about PKD and any other health concerns you may have. This will assist you in knowing your choices and allow you to make well-informed decisions. Pay attention to symptoms and write them down, including important details: when symptoms started; what time(s) of day they occurred and how frequently; how long they lasted and what makes them better or worse. This will give your doctor a clear picture of your condition. Ask questions and make certain you understand the answers. Don’t be afraid to ask your doctor to repeat the answer if you don’t understand.

**What about prescription medications?**

Know the medications you are taking. When one of your doctors prescribes a drug, be sure to ask questions:

- What does this drug do?
- What are the advantages of this drug?
- What are the possible side effects?
- Is it dangerous to take this drug with any foods, beverage, or other prescription or over-the-counter medications?
- Will any other condition I have be aggravated or made worse by this drug?
- Are there alternatives to this drug (generic brand, other medication, different treatment)?
Are there treatments available?

Tolvaptan (brand name JYNARQUE™), a new drug belonging to the family of vasopressin receptor antagonists, was recently approved by the US Food and Drug Administration for use in ADPKD patients at high risk for progression to ESRD.

Two large placebo-controlled clinical trials (the TEMPO or “Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes” and the REPRISE or “Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy in ADPKD”) have evaluated the safety and efficacy of tolvaptan in two complementary populations (in terms of GFR). Both studies show that tolvaptan (compared to placebo) slows the annual rate of decline in kidney function. TEMPO also showed that kidney growth decreased by approximately one third (31% reduction in the annual rate of decline of eGFR with tolvaptan compared to placebo).

The most commonly observed side effects of the drug are: increased urination (usually around a gallon a day), increased thirst, fatigue, dry mouth and skin, and occasionally an increase in serum creatinine and in liver function tests.

Due to the potential risk of liver injury (<4% of the patients), this drug was approved to be dispensed through a restricted distribution program called the JYNARQUE Risk Evaluation and Mitigation Strategy (REMS) Program.

Who is a good candidate to benefit from tolvaptan?

The decision to give tolvaptan to ADPKD patients should be made after careful assessment of risks (liver toxicity, polyuria, polydipsia), benefits, and affordability on an individual basis in consultation with an experienced physician.

Based on the original design of the TEMPO and REPRISE trials and the FDA approval of tolvaptan for PKD patients at risk of fast progression. We recommend using the following tools to establish who may be at risk for fast progression.

1. If kidney volume measurement is available, a Total Kidney Volume (TKV) >750 ml or Mayo classes 1C, 1D and 1E (this is a TKV measurement adjusted for age).

   Total kidney volume may be easily calculated from measurements taken from an MRI or CT-scan. A TKV of >750 identifies those patients potentially at high risk of loss of kidney function.

   TKV was been further refined, by adjusting for age. Younger patients with bigger kidneys are at higher risk of loss of kidney function then older patients with smaller kidneys. This prognostic model helps us predict who will progress to kidney failure faster, and is called the “Irazabal prognostic enrichment classification” or “Mayo classification.” Patients with a typical presentation of ADPKD (with multiple bilateral cysts) are sorted into 5 classes in this system (1A, 1B, 1C, 1D and 1E). Mayo classes 1C, 1D, and 1E are considered to be at higher risk for rapid progression to ESRD and should be offered tolvaptan.

2. If kidney volume measurement is not available but a kidney length is available, use kidney length >16.5 cm.

   If the kidney length based on an ultrasound study is higher than 16.5 cm, particularly in younger adults, patients should be considered at higher risk of progression.
3. If genetic testing results are available, use PROPKD Score of >6.

If genetic testing results are available, a prognostic tool called PROPKD score has been developed for patients above 35 years of age. The score varies from 0 to 9 and includes six parameters: gender, presence of hypertension before 35 years of age, occurrence of the first urologic event before 35 years of age, PKD1 versus PKD2 mutation, and truncating versus non-truncating PKD1 mutation. Patients with PROPKD scores of >6 should be considered for tolvaptan therapy since they are considered at higher risk for rapid progression.

4. An increase in serum creatinine levels, corresponding to Chronic Kidney disease (CKD) stage 3, also may define a patient at rapid risk of progression.

Who should not take tolvaptan?

Tolvaptan is not approved for children (age < 18) with ADPKD and has not been tested in patients above age of 55 and with GFR < 25 ml/min).

Also, it should not be used in patients with liver impairment or injury (except for uncomplicated polycystic liver disease). Other important contraindications include the use of strong CYP3A inhibitors, abnormal serum sodium (particularly hypernatremia), inability to sense or respond to thirst, hypovolemia, or uncorrected urinary outflow obstruction.

Can I afford tolvaptan?

At current time, tolvaptan is extremely expensive (around $13,000 per month). Usually a prior authorization from your insurance company is needed to approve the treatment, before the medication can be dispensed. You will need to sign a form acknowledging that you understand and accept the mandatory monitoring program for use of tolvaptan. Then your nephrologist will file for prior authorization.

Once approved, your out-of-pocket cost (co-pay) will be communicated with you by the insurance company. This could be as low as $10 per month for many insured patients but also as high as several thousand dollars per month. Additional Patient Assistance Programs are available through the manufacturer for uninsured/underinsured patients.

How do I take tolvaptan? What is the usual dosing and titration regimen?

Tolvaptan has to be taken twice a day (early morning and mid afternoon). The dosing has to be titrated from a minimal dose of 45+15 mg to a maximum of 90+30 mg as long as you can tolerate the dose. The steps of titration have to be at least one week a part (up to 4 weeks). Close monitoring of your kidney function and liver tests are required during the titration. Once an appropriate dose is established for you, you will remain on it with continued monitoring.

If you are sick, or unable to drink water (general anesthesia, lack of access to water), you should stop taking the medication until that condition is resolved.

Patients should be monitored for possible interactions between tolvaptan and commonly used drugs in (diuretics, calcium channel blockers, and other strong inhibitors of the CYP3A4), which were excluded in the TEMPO and REPRISE trials.

What kind of monitoring is needed when I am taking tolvaptan?

To ensure your safety, it is necessary to measure your liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin) before initiating treatment, at two and four weeks after initiation, then monthly for 18 months (20 liver function test check points during the first 18 months) and then quarterly while on the medication.
If liver toxicity is detected, (increase of those tests at >2 times the upper limit of normal), your doctor should immediately discontinue the drug and repeat those tests on close follow-up intervals.

Monitoring of kidney function is also recommended during the titration period, or if patients have clinical problems.

Patients should be monitored for possible interactions between tolvaptan and commonly used drugs (diuretics and calcium channel blockers). The use of tolvaptan is contraindicated in patients taking strong inhibitors of the CYP3A4.
PKD can affect organs other than the kidneys (table 1 on page 7). The following list of potential problems may look long and overwhelming, but it is important to remember that most people do not have all of these problems. If you have PKD, you and your family should be aware of the following possibilities so you can play an active role in understanding and managing your own healthcare.

1. Liver cysts

More than 80 percent of patients with PKD develop liver cysts during their lifetime. Liver cysts can occur in those under the age of 30, but are usually small and detectable only by MRI scanning. The liver can remain normal in size with a few cysts or can become enlarged. Even with increased liver size from PKD, the amount of functional liver tissue remains more than adequate. This means it is highly unlikely that patients with severe polycystic liver disease (PLD) would develop liver failure. Although not common, severe PLD can present with symptoms due to a “mass effect” (i.e., abdominal fullness, pain, early satiety (feeling full), ankle swelling and fluid accumulation within the abdomen). In the severe and symptomatic cases, cyst decompression may be needed. When a very few very large cysts are present, additional surgical intervention may be recommended to take care of these cysts. Partial liver resection may be considered in selected cases. This should only be performed at specialized centers with experienced surgeons.

Liver cysts occur more often in women than men. Women develop liver cysts at a younger age and have more and larger cysts than men. Women with previous pregnancies have more numerous and larger liver cysts than women without any pregnancies. This observation suggests that female hormones may influence the development of liver cysts. Because estrogen may be a factor in liver cyst growth, the benefits of estrogen replacement therapy (ERT) and the risk of PLD must be carefully weighed. A Nurses’ Health Study has disproved any benefit of estrogen to prevent cardiovascular disease; however, estrogen replacement therapy is protective against osteoporosis and decreases vasomotor instability — a cause of hot flashes in post-menopausal women. Thus, the risk of estrogen for aggravating PLD against its potential benefits on post-menopausal symptoms and osteoporosis needs to be weighed. Work with your doctors (nephrologist, Ob/Gyn, and general practitioner) to determine what would be the best course for you.

Women with PKD who use estrogen after menopause should have a baseline ultrasound of their liver before they start ERT and every two years thereafter. This will help your doctor evaluate if liver cysts are increasing in number and/or size. It is unclear at this time if it is better to take ERT in pill form or by skin patch. Theoretically, the patch would be a better choice since oral therapy provides high concentrations of estrogen directly to the liver.
Finally, there is no data looking at the effect of low-dose oral contraceptives on women with ADPKD. If you have significant PLD, you should discuss the use of these with your doctor.

One complication of PLD is liver cyst infection. Symptoms range from fever to pain in the upper right side of the abdomen. These symptoms need to be reported to your doctor as soon as possible. Treatments of an infected liver cyst usually require antibiotic therapy and occasionally needle drainage.

2. Mitral valve prolapse (MVP)

*Mitral valve prolapse (MVP)* is a condition where the valve separating the top and the bottom of the left side of the heart does not close properly. Sometimes this causes blood to leak back to the top part of the heart. This is called *regurgitation* and can be heard during an examination of the heart as a heart murmur. Symptoms that can be associated with MVP are palpitations, a feeling that the heart is running away or that there are extra beats in the heart and chest pain that is not associated with exercise or exertion. MVP occurs with increased frequency in patients with PKD as compared to the general population but rarely causes any significant clinical problems.

MVP is usually confirmed with an ultrasound of the heart valves called an echocardiogram. If MVP is present and causes palpitations that are bothersome, treatment with medications is available. Restricting the use of caffeine, alcohol, and cigarettes may be enough to decrease or stop the palpitations in many cases.

Rarely, an infection of a heart valve can occur as a complication of MVP. Although not a common occurrence, it can lead to destruction of the heart valve. Therefore, if you have MVP and a heart murmur, inform all doctors who care for you.

3. Aneurysm

An *aneurysm* is an outpouching in a blood vessel. The bigger the aneurysm, the more likely it is to leak or rupture.

*Intracranial (brain) aneurysms* occur in the blood vessels of the brain (Figure 9). Symptoms can include sudden severe headache, pain in moving your neck, nausea/vomiting, difficulties with speech or movement and/or loss of consciousness. A ruptured aneurysm can be fatal. If you know you have an aneurysm (or have a family history of aneurysms) and you are experiencing any of these symptoms, you should call emergency services immediately.

Recent studies done in the United States have shown that PKD patients have about a 5 – 10 percent risk of developing intracranial aneurysms. This is about five times the risk of the general population. They also seem to cluster in certain families – that is, if a member of your family has an aneurysm or has ruptured an aneurysm, you may be at a higher risk of having an aneurysm yourself.

Because the risk for aneurysm is small, not everyone with PKD needs to be tested. However, people who have PKD and a family history of aneurysm should be tested, along with those whose job or hobbies would put them or others at risk if they lost consciousness (such as those who fly airplanes or drive buses). It is important to inform your doctor if you have a
family history of intracranial aneurysms and/or if you have a high-risk occupation or hobby. Aneurysms in other vessels such as the aorta have also been reported.

**Magnetic resonance angiography (MRA)** is the preferred test to screen for an aneurysm. When an aneurysm is detected on an MRA, an arteriogram is usually performed. This test is more invasive and is done by putting dye directly into the blood vessels which will more clearly show if there is an aneurysm and how large it is.

If an aneurysm is found, surgical repair or a therapeutic coil (a device placed in the aneurysm) may be recommended. The need for surgery is performed depends on the size and location of the aneurysm. Often an aneurysm can be repaired surgically before it leaks or ruptures. If you have had one aneurysm, you may develop others over time and need periodic follow-up. Recent studies suggest that patients with a positive family history of ICA should be screened with MRA every 5–10 years.

### 4. Hernias

Both inguinal and umbilical hernias are more common in those with PKD. Inguinal hernias are outpouchings in the area of the groin. Umbilical hernias are outpouchings at or near the navel [Figure 10]. These should be surgically repaired if they are large or are causing problems, just as they would be in someone who does not have PKD.

### 5. Diverticulosis

**Diverticula** are outpouchings on the large intestine (colon). It appears that patients with PKD who are on dialysis or have had a transplant have diverticula more often and also have more complications from diverticula, including infection, than patients with other kidney diseases.

**Diverticulitis** can occur when diverticuli become infected, requiring treatment with antibiotics. This is a rare occurrence.
How can I tell if my kidneys have failed?

Kidney failure is also known as *end-stage renal disease (ESRD)*, when normal kidney function declines and needs to be replaced by dialysis or transplant. At this point, GFR is at 10 or less, and kidneys can no longer balance electrolytes and acids in the blood or remove wastes and excess water.

Symptoms that some people experience during this time could include:

- Decreased energy
- Weakness
- Shortness of breath/fluid building up in the lungs
- Weight loss
- Swelling of the legs
- Itching
- Loss of appetite
- Nausea and/or vomiting
- Metallic taste in the mouth
- Mild to moderate depression
- Decreased ability to think problems through

It is important to keep your doctor informed of your symptoms so she/he can help you decide when it’s time to start dialysis or be evaluated for transplant.

Blood tests will show that your blood urea nitrogen (BUN) and creatinine are not being properly eliminated by the kidneys and are building up in the blood. These tests may also show that your electrolytes and pH are out of balance.

Generally, planning for kidney replacement therapy (dialysis) is done when your kidney function is at about 25 percent but most patients with PKD can wait until their kidney function drops to below 10 to absolutely need dialysis. If you wait until you are very sick, it will take you much longer to recover and may require hospitalizations.
Dialysis is a kidney replacement option that does some of the things healthy kidneys do. It is needed when your own kidneys fail or can no longer function well enough to take care of your body’s needs.

Multiple types of dialysis are in two broad categories: hemodialysis and peritoneal dialysis.

Hemodialysis

Hemodialysis (Hemo) uses a machine to clean waste from your blood. Your blood flows on one side of a natural or artificial membrane, with special fluid (dialysate) on the other side. The membrane permits waste molecules (extra fluid, electrolytes, etc.) that have built up in the blood to pass into the fluid and be removed, thus cleaning your blood.

- **HOME HEMODIALYSIS**: dialysis that is done at home with an assistant and your own dialysis machine
- **IN-CENTER, SELF-CARE HEMODIALYSIS**: dialysis done in a center with you doing as much as possible with the assistance of staff at the dialysis center
- **IN-CENTER HEMODIALYSIS**: dialysis that is done in a center with the staff providing all of the care

Dialysis access

To prepare for hemodialysis, your doctor will require you to have a vascular access surgically created. This will provide a port for your blood to flow through to be cleaned by the dialysis machine. It will stay with you as long as you are on dialysis. There are three types of vascular access for dialysis.

Two types are designed for long-term use:

1. An arteriovenous (AV) fistula is a surgically created connection from an artery to a vein. Your surgeon will typically place an AV fistula in the forearm or upper arm as an outpatient procedure; occasionally doctors require patients to stay overnight after the procedure. The procedure is done under local, regional or general anesthesia. An AV fistula generally requires two to three months to mature before it can be used; if it fails to mature, the procedure must be repeated.
   
   This type of access is recommended because it:
   
   > Provides good blood flow for dialysis
   > Lasts longer than other types
   > Is less likely to get infected or cause blood clots

2. An arteriovenous graft is a looped, plastic tube that connects an artery to a vein. This type of access is also placed in a surgical procedure using regional or general anesthesia. You can generally use an AV graft two to three weeks after surgery, although some newer types
of AVG can be used the same day. Infection or clotting are more likely with an AV graft than with an AV fistula but a well cared for graft can last several years.

The third type of access is not intended for long-term use:

3. A **venous catheter** is a tube inserted into a vein in your neck, chest, or groin area. The tube splits in two after it exits your body to carry blood to the dialyzer and then back again. A venous catheter will be used if you progress to kidney failure quickly and there is not enough time for placement of a permanent access before starting dialysis. This type of access is more likely to become infected, cause clots, etc. It is better to begin hemodialysis with a fistula or graft.

Caring for your vascular access is key to your health:

- Keep the access area clean at all times
- Use the access only for dialysis
- Do not bump or cut the access
- Check the “thrill” in the access daily—the “thrill” is the rhythmic vibration felt over their access
- Report any signs of infection including redness, tenderness and/or pus
- Do not let anyone put a blood pressure cuff on your access arm
- Do not let anyone draw blood from your access arm
- Do not wear jewelry or tight clothes over the access site
- Do not sleep with the access arm under the head or body
- Do not lift heavy objects or put pressure of any kind on the access arm

**Peritoneal dialysis**

**Peritoneal dialysis (PD)** a type of dialysis that removes extra fluid, electrolytes and wastes using the lining of the abdominal cavity (peritoneum). PD requires a soft plastic tube be surgically placed in your belly. A sterile cleansing fluid (dialysate) is then put into your belly via the tube to filter the fluid.

There are two ways to do peritoneal dialysis:

1. **Continuous ambulatory peritoneal dialysis (CAPD)** is done on a continuous basis. It is machine-free and happens while you go about your normal life, including work, school, or social activities. It is done by hooking a plastic bag of cleaning fluid to the tube in your belly then raising the bag to shoulder level. This allows gravity to pull the fluid into your belly. When the bag is empty, it is removed and thrown away. After 30 to 40 minutes, the fluid is drained from your belly (through the plastic tube) and discarded. This process is usually done three, four, or even five times each day.

2. **Continuous cyclic peritoneal dialysis (CCPD)** uses the same as CAPD, but it is done at night using a machine to make the exchanges while you sleep.

**How will I choose the dialysis type for me?**

When your kidney function has declined to the point that replacement therapy is needed, your doctor and the dialysis team will discuss in detail all the options available to you. When you get close to needing dialysis, you’ll take a tour of a dialysis facility and talk to others on dialysis and the nursing staff to get a sense of what will work best for you.
When your GFR nears 20, you can start considering a transplant. Making the decision to be evaluated for a kidney transplant should be considered carefully with your doctor and/or nephrologist and your immediate family. Because of the way kidneys are allocated (read more on this below) combined with the progressive nature of PKD, it is important to consider being listed early — before dialysis begins. Although you cannot be officially listed until your GFR is at 20 or below, it is important to gather information early. You may have to start the conversation with your physician; don’t wait for them to bring it up.

Transplant evaluation

When you and your doctor agree it is time for you to be evaluated for a transplant, you undergo a series of tests to assess your options. You’ll be evaluated for potential issues like heart disease, obesity, cancer screening and diabetes. A social worker or transplant coordinator will discuss the logistics with you as well; things like transportation, housing, financial and family support will all be considered.

Screening tests

There are several screening tests to determine your blood and tissue type, which are needed to match you to a donor kidney. In addition to the tests below, other tests may be required depending on your age, medical history, etc. A mammogram, colonoscopy, or other tests may be required.

1. **Blood type** is the first test; it will tell you which of the four blood types — A, B, AB, or O — you are. You must have a blood type that is compatible with your donor for the transplant to be successful.

   Compatible blood types:
   - If your blood type is A, donor blood type must be A or O
   - If your blood type is B, donor blood type must be B or O
   - If your blood type is AB (universal recipient), donor blood type must be A, B, AB or O
   - If your blood type is O (universal donor), donor blood type must be O

   The Rh type (+ or −) is not a factor in donor matching.

2. **Human leukocyte antigens (HLA)** (also called tissue typing) is the second blood test you’ll undergo. The HLA are found mostly on white blood cells; they are markers that let your immune system know which cells belong to your body and which do not.

3. **Crossmatch** is another blood test you will undergo. This test tells you what antibodies you have in your body. Antibodies are produced by your immune system when it attacks foreign substances. You make antibodies when you have an infection, are pregnant, have a blood transfusion or undergo a kidney transplant. If you have antibodies to the donor
kidney, your body will fight that kidney until it is destroyed. The crossmatch test is done by mixing your blood with cells from your donor. If the crossmatch is positive, you have antibodies against your donor and should not receive the kidney.

All of these blood tests are required before you can be considered for a transplant. Once the results from all the tests are back, your transplant team will meet to discuss your results. They will discuss your medical and social history (history of drug or alcohol abuse, level of family and financial support, etc.) and make a decision. If they decide you should be listed for a transplant, you are then placed on the United Network for Organ Sharing (UNOS) waiting list.

How do I get a transplant?
There are two ways to receive a new kidney — through a living donation or through a deceased donation.

Living donation
Living donation requires a living person to donate a kidney (or other organ) to someone who needs a transplant. Six thousand organ transplants a year are made possible by living donors. The kidney is the most commonly transplanted organ from a living donor.

Positive aspects of a living donation:

▸ A living donation makes it possible to schedule the transplant surgery at a time convenient for both the you and your donor.

▸ Better genetic matches between you and your donor decrease the risk of organ rejection.

▸ Kidneys from living donors usually work immediately, as the kidney is removed from a healthy donor and transplanted right away in an operating room.

▸ A living donor transplant may reduce or eliminate your time on dialysis and/or years of waiting for a deceased donor organ.

Who can be a living donor?
Potential living donors must be in good overall health, both physically and psychologically. Gender and race are not factors.

Types of living donor transplants

1. DIRECTED DONATION: This is the most common type of living donation. In a directed donation, the donor names a specific person to receive the transplant. The donor may be:
   > Related: your biological relative, such as a parent, brother, sister, or adult child
   > Non-related: a biologically unrelated person who has a personal or social connection with you, such as a spouse or significant other, a friend or a coworker

2. NON-DIRECTED/ALTRUISTIC DONATION: In this type of donation, the donor does not name a specific person to receive their organ. The match is arranged based on medical compatibility with a patient in need. Some non-directed donors choose never to meet their recipient. In other cases, the donor and recipient may meet at some time, if they both agree, and if the transplant center policy permits it.

3. PAIRED DONATION OR PAIRED EXCHANGE: A paired donation involves two or more pairs of living kidney donors and transplant candidates who do not have matching blood types. The candidates “trade” donors so that each candidate receives a kidney from a donor with a compatible blood type.
For example, in the illustration below (Figure 11), Joan wants to donate to her sister Betty, but they do not have matching blood types. Jim wants to donate to his wife Donna, but they are also not compatible. By “swapping” donors so that Jim matches Betty and Joan matched Donna, two transplants are made possible. This type of exchange often involves multiple living kidney donor/transplant candidate pairs.

4. **BLOOD TYPE INCOMPATIBLE**: This type of donation allows you to receive a kidney from a living donor who has an incompatible blood type. To prevent rejection of the kidney, you undergo specialized medical treatment before and after transplant including the possible removal of your spleen during the transplant. This type of transplant is only done at highly specialized centers.

5. **POSITIVE CROSSMATCH DONATION**: This occurs when you and your living donor do not match due to your antibodies. These antibodies will immediately react against your donor kidney’s cells and cause rejection. Specialized medical treatment is required. This type of donation is only considered when no other living donors match.

Since PKD is a hereditary disorder, can family members be kidney donors? Your family member can be a kidney donor if that individual does not have PKD. The first step for a potential donor is to have an ultrasound of his or her kidneys. By the age of 40, most people (83 to 90 percent) at risk for inheriting PKD can be diagnosed with an ultrasound. In the younger at-risk individuals who are deemed negative by ultrasound, an MRI or genetic testing can be used to provide further certainty in excluding milder forms of PKD. If your family member does not have the disease, the transplant team will further evaluate to make sure there are no other risks for that individual to donate a kidney.

**Other considerations for living donation**

- **Costs**: Most medical costs associated with living donation are covered by your (the recipient) insurance. The government requires all certified transplant centers to charge your insurance an “acquisition fee” when you receive a transplant. The medical costs related to your donor’s medical evaluation, transplant procedure and postoperative care, called the “donor protocol” are covered by this fee. Anything that falls outside of this protocol is not covered. These non-covered and, thus, out-of-pocket costs could include annual physicals, travel, lodging, lost wages, dependent care and other non-medical expenses. Your donor must agree to pay these expenses and must prove that they have the financial capacity to do so.

- **Disability Pay**: If your job provides disability insurance coverage, then you will most likely be entitled to disability pay. Check with your employer for details.
When will the transplant take place?
This decision is made jointly by the transplant team, by you, and by your donor. The transplant team, particularly the doctors involved directly in your care, will determine as accurately as possible the best time to do the transplant, based on your medical condition.

Once the transplant is scheduled, will it definitely happen?
A number of events could happen that may change the date of the transplant.

For example, your condition might deteriorate to the point that you are too sick to receive the transplant. Or you or your donor might develop an infection or some other condition that would need to be treated before the transplant could be done.

Additionally, your donor has the right to change his or her mind. This is why it is so important to encourage your donor to take the time and give the consideration necessary to explore the process and fully understand all the benefits and risks.

Deceased donation
In the United States, most kidney transplants come from deceased kidney donors. Deceased donors are most often individuals who die from accidents, or sudden death, and their next of kin consent to organ donation.

Donor organs are matched to waiting recipients by a national registry called the Organ Procurement and Transplantation Network (OPTN). This registry is operated by an organization known as the United Network for Organ Sharing (UNOS).

When should I start the process to be listed on the registry?
When your GFR is right at or just above 20, you should ask your doctor about the steps it takes to be listed for a transplant. There are many steps, including an evaluation by a transplant center affiliated with OPTN. Some kidney transplant centers would evaluate you when your GFR falls below 30, but you will not be placed on the active transplant list until your GFR falls below 20.

Kidney allocation system (KAS)
The current KAS aims to provide recipients with longer function with their transplanted kidney by matching the donated kidney that has the longest potential life with the recipient who has the longest potential life with that kidney.

Once you are approved to be listed for a transplant, you will be assigned an estimated post-transplant survival score (EPTS) — a percentile score that ranges from zero to 100. The score is based on how long you will need a functioning kidney as compared to all other transplant candidates on the list. If you have an EPTS of 20, it means that you will need a kidney longer than 80 percent of all other candidates. Your EPTS will be electronically updated daily.

To determine your EPTS, four factor values are entered into a mathematical formula:
1. Whether or not you are diabetic
2. Your current age
3. If you are on dialysis and, if so, for how long
4. Whether you have had a previous transplant of any organ

Each available deceased kidney available for transplantation is assigned a kidney donor profile index (KDPI) score — a percentile score ranging from zero to 100. The KDPI is associated with
how long the kidney is likely to function as compared to other kidneys, based on information about the donor. A KDPI score of 60 means that the kidney is likely to function longer than 40 percent of other available kidneys.

The KDPI is calculated based on factors including:

- Age
- Height
- Weight
- Ethnicity
- Cause of death
  - Loss of heart function?
  - Loss of brain function?
  - Stroke?
- History of high blood pressure
- History of diabetes
- Exposure to Hepatitis C Serum creatinine

**How is the EPTS and KDPI used to allocate kidneys?**

When a kidney becomes available and it is given a KDPI score, the EPTS scores of all recipients are considered. The 20 percent of kidneys expected to last the longest (those with a KDPI score of 20 or less) will first be offered to patients likely to need a transplant the longest (those with an EPTS of 20 or less). If a kidney with a KDPI of 20 or less is not accepted for any of these patients, it will then be offered to any other person who would match, regardless of their EPTS score.

Kidneys with high KDPI scores are expected to function for a shorter amount of time than others. They may be best used to help candidates who are less able to stay on dialysis for a long time, thus needing a kidney very quickly.

**Does the KAS negatively impact PKD patients?**

A common concern is that as a PKD patient, you receive fewer transplants because you would not be accumulating time on dialysis, as your kidney function declines more slowly. However, the remedy for this is to be evaluated and listed at a GFR of 20 percent. In this case, based on the natural rate of progression of PKD, most patients should have at least several years of waiting time before being faced with dialysis, and so “pre-emptive” (before dialysis begins) transplantation should still be a common option.

A second concern is that “all the young donors’ kidneys will be given to other groups.” This is a valid concern because PKD patients are often older on average when you reach stage 4–5 CKD. However, two points must be considered:

1. Even people into their 60s can have an EPTS under 20.
2. 80 percent of kidneys donated are allocated to people with an EPTS over 20, and the vast majority of those kidneys will serve their recipient extremely well.
Will my kidneys be removed before or after I have a transplant?

Removal of a polycystic kidney, a process called nephrectomy, before a kidney transplant is generally not performed unless you have a history of:

- Kidney cyst infections
- Severe bleeding from the cystic kidney
- Cancer of the cystic kidney
- Kidneys so large there is no room for a new kidney to be transplanted
- Kidneys are very uncomfortable or cause a lot of pain due to their size
- Malnutrition due to kidney size, impairing food intake

If one or both of your kidneys are removed, the timing will depend on your individual case as well as the center where you are having your transplant. They can remove one or both kidneys before, during, or after transplant.

Does everyone with PKD eventually need dialysis or a transplant?

Although everyone with the PKD gene develops kidney cysts, not everyone progresses to kidney failure, and if you do it is generally not before age 40. More than 50 percent of people with PKD will develop kidney failure by age 50. Some PKD patients have relatively normal kidney function until their 40s or 50s, but when function does begin to decline, it can drop rapidly — in the course of just a few years — rather than the slow decline seen in other kidney diseases.

Many people with a very mild form of PKD are unaware of their status and thus are never diagnosed.

We estimate that at least 10 percent of PKD patients will never reach the point of needing dialysis in their lifetime.

Although we still don’t know exactly how kidney failure happens in PKD, we do know some of the risk factors associated with more rapid progression ESRD. These risk factors include:

- Inactivating (also called truncating) PKD1 mutations (see genetics section for more information) as opposed to PKD2 and non-inactivating (non–truncating) PKD1 mutations
- Being male may be associated with more severe disease than females
- Being diagnosed with cysts at a young age
- High blood pressure
- Large kidneys
- Multiple episodes of blood in the urine
- Being a woman with high blood pressure and four or more pregnancies
How are the costs associated with dialysis and transplant covered?

In general, Medicare covers a significant amount of the cost of dialysis and transplantation. To be eligible, a person must have earned Social Security benefits or be the spouse or dependent of someone who has. About 93 percent of those with ESRD are eligible for this benefit.

Medicare covers immunosuppressive drugs for 36 months (three years) after the month of transplant. Medicare will continue to pay for your immunosuppressive drugs with no time limit if:

▸ You were already entitled to Medicare because of age or disability before your ESRD

▸ You became entitled to Medicare because of age or disability after receiving a transplant that was paid for by Medicare or paid for by private insurance that paid primary to your Medicare Hospital Insurance coverage.

For more detailed information regarding Medicare and payment of costs associated with dialysis and transplant, call your local Social Security Medicare office or visit the U.S. Department of Health and Human Services website (see page 52 for a list of resources). Medicaid may cover those who do not qualify for Medicare. A social worker or financial counselor in the dialysis unit or transplant program at your hospital will help you work through the financial issues.

The burden of kidney disease in America:

▸ More than 20 million Americans have kidney disease

▸ Nearly all patients with kidney failure are Medicare beneficiaries, regardless of age, income or disability

▸ ESRD patients account for nearly 7 percent of Medicare costs, but comprise less than 1 percent of Medicare patients

▸ PKD is the fourth leading cause of kidney failure

▸ More than 50 percent of people with PKD will develop kidney failure by age 50
Can I safely have children if I have PKD?

The diagnosis of PKD is most commonly made by pre-symptomatic screening of at-risk patients with a positive family using ultrasonography which is inexpensive, safe, and readily available. Alternatively, incidental findings of kidney cysts in at-risk patients who undergo imaging studies for other indications may also lead to the diagnosis of PKD. In both scenarios, early diagnosis of PKD has become increasingly more common and has important implications for family planning.

Generally, women with PKD who have normal blood pressure and normal kidney function have uneventful pregnancies and deliver healthy babies. Risk factors associated with pregnancy and PKD are due to increased blood pressure. Some women with PKD will develop hypertension during their pregnancy and are more likely to have continued elevations in their blood pressure after delivery. Women who have high blood pressure prior to becoming pregnant have the risk of further elevations in their blood pressure while pregnant and women with complications in their first pregnancy are more likely to have complications in future pregnancies.

It is important for a woman with PKD to be closely monitored during pregnancy whether she has hypertension or not. Increases in blood pressure as well as protein in the urine could signal a serious complication of pregnancy called preeclampsia — a condition where the placenta can be prevented from getting enough blood. If the placenta doesn’t get enough blood, the growth of the fetus can be compromised resulting in low birth weight, premature birth, and other problems for the baby. Most women with preeclampsia still deliver healthy babies.

Pregnancy does not seem to affect the growth of kidney cysts but there appears to be a slight increase in the rate of loss of kidney function in women with hypertension and four or more pregnancies, as compared to PKD women with hypertension who have fewer than four pregnancies.

The decision to have children is a very personal one. Both parents need to discuss the risks involved and the joy associated with having a child. With an affected parent, there is a 50 percent probability of having a child who has inherited the gene for PKD (see genetics section on page 16). Pre-implantation genetic diagnosis (PGD) is now feasible and has been successfully applied in more than 300 genetic disorders for selecting healthy embryos created by in-vitro fertilization (IVF) for implantation. The utility of this new approach in PKD in the context of family planning has not been formally assessed. For more information, please contact your physician for a referral to specialized centers experienced in PGD.

ADPKD and children

ADPKD can be diagnosed before birth or at a very young age. Diagnostic tests performed during pregnancy should be done in conjunction with medical counseling so the test results can be completely understood. For example, knowing your baby could have (or does have) an ADPKD gene does not determine the course or severity of the disease.
There are two different groups of children with ADPKD — those diagnosed before birth or in their first year of life with large cystic kidneys and those who are diagnosed after their first year.

Children who are diagnosed in the first year of life have some special characteristics:

▸ One parent may have severe ADPKD
▸ Some of these severely affected infants may have a related syndrome, which causes a genetic disease called tuberous sclerosis complex, which can also cause kidney cysts — many will not have a family history of having ADPKD or tuberous sclerosis complex
▸ Most are diagnosed in-utero with large kidneys cysts
▸ Most develop high blood pressure (hypertension) in childhood, which should be monitored and treated by a doctor/pediatric nephrologist
▸ Some patients could develop end stage renal disease (ESRD) by their teenage years

Children who are diagnosed after one year of age:

▸ Usually, one of the parents is known to be affected with typical ADPKD
▸ Often have kidney cysts without kidney enlargement

These cases most likely represent incidental findings due to widespread use of ultrasounds and improved resolution of the scans to detect smaller sized cysts.

Almost all children who are diagnosed after the first year of life will have perfectly normal kidney function throughout childhood.

**What kind of medical treatment should a child with ADPKD have?**

Children who have (or who may have) ADPKD should have their blood pressure measured at least every six months. Normal blood pressure varies for different ages and between boys and girls. All children with ADPKD and high blood pressure require treatment and should be seen by a pediatric nephrologist.

Although less common than in adults, signs and symptoms of infection, blood in the urine and/or pain also need to be evaluated by a doctor.

**Should I limit the physical activity of a child who has ADPKD?**

There is no information to support limiting physical activity in any child simply because he or she has ADPKD. It is possible that children with large kidneys and/or large cysts may have more episodes of blood in the urine if they play contact sports such as football, however each child should be evaluated by a doctor on an individual basis.

**Do children with ADPKD have involvement of organs besides the kidney?**

Just as in adults, children who have ADPKD are more likely to have mitral valve prolapse (MVP) and hernias than children who do not have ADPKD. Approximately 12 percent of all ADPKD children will have MVP, but unlike adults, it is unusual for them to have any symptoms. If your child has a hernia, they should be treated as they would in any other child. Children rarely have any of the other manifestations of ADPKD.

**Should I tell my children they have or are at risk of having ADPKD?**

To date, no research has been done on the effect such knowledge would have on children. Generally speaking, there is no need to burden children with information they are too young to understand. Children have a tendency to ask questions when situations arise and, at that
time, usually want simple honest answers. There is no need to go into great detail unless a child asks more questions on the subject.

Children of affected parents need not be tested for ADPKD. They should be monitored by their doctors for hypertension, and have screening urinalyses performed as part of general health visits without actually making the ADPKD diagnosis.

The decision parents make to test a child should include understanding that a negative result in childhood may not exclude the diagnosis later in life. For example, cysts may develop after the imaging study was performed. The added consequences of making the diagnosis in childhood may give the child a label, which could result in discrimination in employment and potentially in life and disability insurance.

Children can be informed of their risk for ADPKD but routine screening is not recommended at this time. When and if therapies become available to prevent the progression of PKD, the decision to screen may change. Young adults at high risk of progression may benefit from current treatments including pravastatin or tolvaptan.

ARPKD and children

What is ARPKD?

Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder occurring in approximately 1 in 20,000 children. It affects boys and girls equally and can cause death in the first month of life. If a child with ARPKD survives the newborn period, the chances of survival are good. For these children, approximately one-third will need dialysis or transplantation by the age of 10.

What can I expect if my child has ARPKD?

Previously thought to be a fatal condition, the prognosis for children with ARPKD has improved dramatically. Twenty years ago, only half of the children born with the disease survived to their 10th birthday, but now that percentage has increased to 85.

The immediate life-threatening issue for infants with ARPKD is lung immaturity. Lung immaturity is caused in part by insufficient amniotic fluid, produced by the kidneys, due to poor prenatal renal function. Severely enlarged kidneys caused by ARPKD also limit breathing by preventing adequate lung expansion. Death in the neonatal period can be as high as 30 to 50 percent. If an infant with ARPKD survives this critical period, kidney failure can become the most prominent life threatening issue. When the newborn’s life isn’t at risk, the biggest health concerns are often regulating blood pressure and the chemical balance of blood.

The improved prognosis for ARPKD may be attributed to improved prenatal sonogram technology, which allows doctors to diagnose many cases of ARPKD prior to birth. Accordingly, the birth of an affected child is better planned so the necessary specialists can be alerted. Importantly, the doctors are able to discuss with the parents what they should expect once the baby is born, advising them that the infant may need a breathing tube, may require dialysis, may have severe liver disease, and will require multiple evaluations and treatments to handle associated complications.

What causes ARPKD?

In recessive disorders such as ARPKD, the child must inherit a copy of the PKHD1 gene from each parent. Since the parents each have only one copy of the disease gene, they do not have the disease and are referred to as “carriers.” Parents carrying the mutated PKHD1 gene have
a 25 percent chance that each child will have ARPKD. There is also a 50 percent chance each child will not have ARPKD but will be a carrier of the disease (Figure 12).

**How is ARPKD diagnosed?**

Typically in ARPKD, the kidneys appear to be larger than normal. In some babies, prenatal ultrasound can detect the enlarged kidneys as early as 18 weeks after conception. Some families may also hear their doctor say the kidneys look “echogenic” (more white) during an ultrasound, which can be an indicator of kidney problems such as ARPKD.

Prenatal genetic testing is possible using samples from either *chorionic villus sampling* or *amniocentesis*. These genetic tests can either involve a direct search of the gene for mutations or an indirect association using linkage analysis. For linkage analysis, DNA samples are required from the fetus, a previously affected child, and the parents.

Another option for pre-natal diagnosis in affected families is a recently developed procedure called *pre-implantation genetic diagnosis (PGD)*. This is an early form of genetic diagnosis that involves the detection of specific genetic abnormalities in single cells taken from fertilized human embryos. The PGD procedure involves in vitro fertilization whereby eggs harvested from a mother are fertilized in a laboratory with the father’s sperm. Then, the
fertilized embryos are tested for ARPKD by removing one or two cells for genetic analysis. Embryos that are diagnosed as free of the disorder are then placed in the uterus with the intent to initiate a pregnancy.

**What happens to my child's kidneys when they have ARPKD?**

In ARPKD, small cysts form in the last section of the nephron, called the collecting tubule. A cyst is a balloon-like widening of the tubule. Due to the numerous nephrons with small balloon-like dilatations, the kidneys can become quite enlarged. In addition, the normal function of the collecting tubule is disrupted. In the normal kidney, the collecting tubule fine tunes the amount of water and acid in the tubular fluid so that the body retains an appropriate amount of water and eliminates excess amounts of acid. In ARPKD, the cystic collecting ducts cannot retrieve water efficiently, causing much more urine production than in children with normal kidneys.

The majority of children with ARPKD have a progressive loss of kidney function. However, the age at which kidney failure develops varies greatly among patients, and, for reasons still unknown, the size of the kidneys does not necessarily correlate with the severity of the disease.

**Are other organs affected by ARPKD?**

ARPKD affects both kidneys and the liver. Affected children may have significant kidney involvement at the time of birth. In-utero, urine production is a critical factor in maintaining normal amniotic fluid levels. When amniotic fluid levels are very low, lung development can be impaired. In some newborns with low levels of amniotic fluid, impaired lung development can result in serious breathing difficulties that require ventilation upon birth and sometimes can cause death.

Children with ARPKD often produce very large volumes of urine and must urinate more frequently than children with normal kidneys. Given the kidney abnormality, urine production in ARPKD children does not slow down at night or even when liquid intake is limited.

High blood pressure is very common in children with ARPKD, and current information indicates that untreated high blood pressure can lead to kidney failure more quickly than if the blood pressure is kept within the normal range with medications.

Children with ARPKD also have the liver abnormality called *congenital hepatic fibrosis (CHF)* that may lead eventually to enlargement of the liver and spleen. In the liver, the abnormality can impede the return of blood from the intestine to the liver. This condition, called *portal hypertension*, can lead to distention and increased pressure in the veins around the esophagus, stomach, and the intestine. This can rupture, leading to possibly life-threatening gastrointestinal bleeding. In addition, portal hypertension can cause spleen enlargement and hypersplenism resulting in low red blood cell, white blood cell and platelet counts.
Core resources

PKD Foundation
1001 E 101st Terr
Suite 220
Kansas City, MO 64131
1.800.PKD.CURE
pkdcure.org

PKD Foundation of Canada (for those living in Canada)
3-1750 The Queensway, Suite 158
Etobicoke, ON M9C 5H5
dnpkd.ca

PKD United Kingdom (for those living in the U.K.)
pkdcharity.org.uk

Published research articles

Chang MY, Ong A.
New treatments for autosomal dominant polycystic kidney disease.

Cornec-Le Gall E, Audrézet MP, Chen JM, et al.
Type of PKD1 mutation influences renal outcome in PKD.

Harris PC, Torres VE.
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

A missense mutation in PKD1 attenuates the severity of renal disease.

Rossetti S, Kubly VJ, Consugar MB, et al.
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

Torres VE, Bankir L, Grantham JJ.
A case for water in the treatment of polycystic kidney disease.
Additional resources

**American Kidney Fund**
11921 Rockville Pike
Suite 300
Rockville, MD 20852
1.800.638.8299
kidneyfund.org

**American Society of Nephrology**
1510 H Street, NW
Suite 800
Washington, D.C. 20005
202.640.4660
asn-online.org

**American Society of Transplantation**
1120 Route 73
Suite 200
Mt. Laurel, NJ 08054
856.439.9986
myast.org

**Clinicaltrials.gov — A service of the U.S. National Institutes of Health**
clinicaltrials.gov/ct2/help/for-patient

**DaVita Dialysis**
2000 16th St.
Denver, CO 80202
1.888.484.7505
davita.com

**DASH Diet**
dashdiet.org

**Fresenius Medical Care**
920 Winter Street
Waltham, MA 02451-1457
1.800.662.1237
fmcna.com

**Medicare**
7500 Security Boulevard
Baltimore, MD 21244-1850
1.800.MEDICARE (633.4227)
medicare.gov

**ESRD-specific Medicare Information**
medicare.gov/people-like-me/esrd/getting-medicare-with-esrd.html

**Medicare: Coverage of Kidney Dialysis and Kidney Transplant Services**
Medicare Handbook (CMS Publication #10128)
medicare.gov/Pubs/pdf/10128.pdf

**Organ Procurement and Transplantation Network**
P.O. Box 2484
Richmond, VA 23218
optn.transplant.hrsa.gov

**United Network for Organ Sharing**
P.O. Box 2484
Richmond, VA 23218
804.782.4800
unos.org

**U.S. Department of Health and Human Services**
200 Independence Avenue, S.W.
Washington, D.C. 20201
1.877.696.6775
hhs.gov

**Affordable Care Act (part of HHS)**
hhs.gov/healthcare/facts/timeline/index.html
0–9

24-hour urine collection
A test done in combination with the blood creatinine test to determine kidney function, called creatinine clearance and is an approximation of glomerular filtration rate

A

ACE inhibitors
Angiotensin converting enzyme (ACE) inhibitors; a group of drugs commonly used to treat hypertension in PKD patients

ADPKD
Autosomal dominant polycystic kidney disease; the more common form of PKD, it occurs in approx. 1 in 500 live births

Aldosterone
A hormone that causes the body to retain salt and lose potassium

Amniocentesis
A test used in prenatal diagnosis of chromosomal abnormalities in which a small amount of amniotic fluid, which contains fetal tissues, is sampled from the amniotic sac surrounding a developing fetus, and the fetal DNA is examined for genetic abnormalities

Amniotic fluid
The protective fluid contained in the amniotic sac of a pregnant female; the fluid is partially supplied by fetal urine, which is produced by the fetal kidneys; in ARPKD, poor prenatal renal function causes a reduction in this fluid

Aneurysm
An outpouching in a blood vessel, which can leak or rupture

Angiogram
Procedures that utilize contrast dye injected into the blood vessels in order to clearly visualize them; it is typically used when an aneurysm is suspected or to look for blockages in heart vessels

Angiotensin
A powerful constrictor of blood vessels; it stimulates the production of aldosterone

Angiotensinogen
A substance in the blood that forms a hormone called angiotensin

ARBs
Angiotensin receptor blockers (ARBs); a group of drugs commonly used to treat hypertension in PKD patients

ARPKD
Autosomal recessive polycystic kidney disease; occurs in approx. 1 in 20,000 live births

arteriovenous (AV) graft
A looped, plastic tube that connects an artery to a vein

arteriovenous (AV) fistula
A surgically-created connection from an artery to a vein

Aspirate
To draw fluid by suction

Autosomes
A chromosome that is not a sex chromosome; most cells in our body have 22 sets of autosomes

B

Bladder
A muscular sac in the pelvis that collects urine
Blood pressure
A measurement of the force of the blood as it flows through the body

Blood type
A classification of blood based on the presence or absence of antigens on the surface of red blood cells; there are four major blood types — A, B, AB and O; your blood type must be compatible with a potential kidney donor

Blood type incompatible
A transplant option that allows you to receive a kidney from a living donor who has an incompatible blood type; specialized medical treatment is required before and after transplant to prevent rejection

Blood urea nitrogen (BUN)
A measure of kidney function; urea nitrogen is the waste product of dietary protein, so if the urea nitrogen builds up in the blood, it is a sign of decreased kidney function

Caffeine
A substance found in coffee, tea, soft-drinks, etc.; it is generally considered best for PKD patients to limit caffeine intake to less than 200–250 mg daily

Calcium
A mineral that the body needs for strong bones and teeth; calcium may form stones in the kidney

Calcium oxalate
A common type of crystal that can lead to kidney stones

Carrier
An individual who carries one copy of a recessive gene like that for ARPKD; they do not have the disease but can pass the mutation on to their offspring

Cell proliferation
Cell growth

Chorionic villus sampling (CVS)
A test used in prenatal diagnosis of chromosomal abnormalities in which a sample of chorionic villi is removed from the placenta for testing

Chronic pain
Pain that is constant over a long time; long-term pain

Computed tomography (CT)
A screening test that may involve radiation or iodinated contrast dye, which can be toxic to kidneys

Congenital hepatic fibrosis
A liver abnormality common in children with ARPKD; it may lead eventually to enlargement of the liver and spleen

Creatinine
A waste product of muscle metabolism; the level of creatinine in the blood is a measure of kidney function

Creatinine clearance
A test to calculate approximately how much actual kidney function you have

Crossmatch
A blood test that tells you what antibodies you have in your body

Cyclic AMP (cAMP)
Signaling molecule in cells that form tubules in the kidneys; abnormalities can lead to cyst formation

Cystitis
A UTI with infection in the bladder

Diastolic pressure
The bottom/second number of the blood pressure reading; it measures the pressure when the heart is relaxing between beats

Direct mutation analysis /DNA sequencing
A type of DNA testing requires only a single sample from the person being tested; an analysis of the DNA sequences of the PKD1 and PKD2 genes is performed

Directed donation
The most common type of living donation; when a living donor (see living donation) names the person who will receive their organ

Diverticula
Outpouchings on the large intestine
**Diverticulitis**
Can occur when diverticuli rupture or become infected

**DNA testing**
A way to find out if you have a PKD gene
See also gene linkage testing and direct mutation analysis

**E**

**Echocardiogram**
An ultrasound of the heart

**End-stage renal disease (ESRD)**
When normal kidney function declines and needs to be replaced by dialysis or transplantation; also known as kidney failure; typically considered to occur when GFR is at 10 or less

**Erythropoietin**
Also called EPO; a hormone made in the kidney that tells the bone marrow to make red blood cells; if your kidneys fail or are removed, you must be given EPO via blood transfusions or a synthetic supplement

**Estimated post-transplant survival score (EPTS)**
A percentile score that ranges from zero to 100 and is assigned to each potential transplant recipient; the score is based on how long you will need a functioning kidney as compared to all other transplant candidates on the list

**G**

**Gadolinium**
Special dye used to improve visualization in MRIs

**Gene linkage testing**
A type of DNA testing that can determine if you have PKD with 99 percent probability in those with a family history; requires samples from several family members and looks for “markers” in the DNA; a detailed family history is also required

**Glomerular filtration rate (GFR)**
The test used to check how well the kidneys are working; it estimates how much blood passes each minute through the glomeruli (tiny filters in the kidneys that filter waste from the blood)

**Glomerulus**
A small tuft of blood capillaries in the kidney, responsible for filtering out waste products

**H**

**Hematuria**
Blood in the urine

**Hemodialysis (Hemo)**
A procedure that removes extra fluid, electrolytes and waste from blood using a dialysis machine

**Hernia**
Occurs when the contents of a body cavity bulge out of the area where it is normally contained; two types of hernia, inguinal and umbilical, are more common in those with PKD

**Human leucocyte antigens (HLA)**
Markers that let your immune system know which cells belong to your body and which do not; used in tissue typing

**Hypertension**
High blood pressure; it affects about 60–70 percent of PKD patients and begins early in the course of the disease

**I**

**Inactivating mutation**
A change in the DNA that leads to a reduced or complete loss of function of a protein

**Intercranial aneurysm**
An aneurysm that occurs in the blood vessels of the brain

**K**

**Kidney Allocation System (KAS)**
The system that allocates deceased kidney donations to waiting recipients

**Kidney donor profile index (KDPI)**
A percentile score that ranges from zero to 100 and is assigned to each available deceased kidney; the score is associated with how long the kidney is likely to function as compared to other kidneys, based on information about the donor
Kidney stones
Small, hard deposits made of minerals and acid salts that form inside the kidneys

L
Lithotripter
A machine that uses ultrasound waves to treat large kidney stones
Liver function tests
Blood tests that help determine how well the liver is functioning
Living donation
When a living person chooses to donate their kidney (or other organ) to someone who needs a transplant

M
Magnesium
A mineral in the body that is important for metabolism; a deficiency has been associated with high blood pressure
Magnetic resonance arteriogram (MRA)
A type of MRI used to visualize the blood vessels in the brain to screen for aneurysms; it is similar to an MRI scan but does not use contrast dye or radiation
Magnetic resonance imaging (MRI)
A screening test that uses a powerful magnetic field, radio frequency pulses and a computer to produce detailed pictures of the inside of the body
Microscopic hematuria
Small amounts of blood in the urine
Mitral valve prolapse (MVP)
Occurs when the valve between your heart's left upper chamber (left atrium) and the left lower chamber (left ventricle) doesn't close properly
Mutation
An unintended change or typo in a person's genetic code

N
National Institutes of Health (NIH)
The agency of the U.S. government primarily responsible for biomedical and health-related research
National Organ Procurement and Transplantation Network (OPTN)
The national registry where donor organs are matched to waiting recipients
Neonatal period
The first month of life of a newborn
Nephrectomy
A surgical procedure to remove one or both kidneys
Nephrogenic Systemic Fibrosis (NSF)
A rare but serious complication that can arise from the use of gadolinium
Nephrologist
A doctor who specializes in kidneys
Nephrons
Tiny filters in the kidney made of thin blood vessels; each kidney has about one million nephrons
Neuroradiologist
The type of surgeon who repairs aneurysms
Non-directed donation
When a living donor (see living donation) does not name a specific person to receive their organ; also called altruistic donation
Non-inactivating mutation
A change in the DNA that does not lead to a loss of function of a protein
Non-truncating mutation
A change in the DNA that does not truncate or shorten the protein
NSAIDs
Non-steroidal anti-inflammatory drugs like aspirin or ibuprofen; these are not advisable for PKD patients to take
P
Pain clinic
A clinic or office that uses biofeedback and supports groups to help manage pain.
Paired donation
A transplant option for candidates who have a living donor who is medically able, but cannot donate a kidney to their intended candidate because they are incompatible (i.e., poorly matched); consists of two or more kidney donor/recipient pairs whose

blood types are not compatible; the two recipients trade donors so that each recipient can receive a kidney with a compatible blood type

**Peritoneal dialysis (PD)**
A type of dialysis that removes extra fluid, electrolytes and waste using the lining of the abdominal cavity

**Peritoneum**
The abdominal cavity

**PKD**
Polycystic kidney disease; a genetic disease that causes uncontrolled growth of cysts in the kidneys; two forms (ADPKD and ARPKD)

**PKD1**
The gene that provides instructions for the polycystin-1 protein; a mutation of the PKD1 gene will cause a person to have ADPKD

**PKD2**
The gene that provides instructions for the polycystin-2 protein; a mutation of the PKD2 gene will cause a person to have ADPKD

**PKHD1**
The gene that codes for ARPKD

**Polycystic liver disease (PLD)**
More than 80 percent of PKD patients will develop liver cysts; severe cystic liver disease is uncommon

**Polycystin**
A protein that is encoded by the PKD1 and PKD2 genes; regulates many important tubular cell functions

**Polycystin-1**
The protein that is coded by the PKD1 gene

**Polycystin-2**
The protein that is coded by the PKD2 gene

**Portal hypertension**
An abnormality in the liver which can impede the return of blood from the intestine to the liver; can cause spleen enlargement and hypersplenism resulting in low red blood cell, white blood cell and platelet counts; can lead to distention and increased pressure in the veins around the esophagus, the stomach, and the intestine, which can rupture, leading to possibly life-threatening gastrointestinal bleeding

**Positive crossmatch**
A transplant option that allows you to receive a kidney from a living donor who does not match you due to antibodies; specialized medical treatment is required before and after transplant to prevent rejection; this type of donation is only considered when no other option is available

**Potassium**
A substance essential to all living cells found in most foods; supplements should not be taken without consultation by your doctor or dietician

**Pre-emptive transplantation**
Having a transplant before dialysis is required

**Pre-implantation genetic diagnosis**
A form of early genetic diagnoses that uses vitro fertilization; eggs harvested from a mother are fertilized in a laboratory with the father’s sperm then the fertilized embryos are tested for ARPKD; embryos that are diagnosed as free of the disorder are then placed in the uterus with the intent to initiate a pregnancy

**Proteinuria**
Protein in the urine

**Pyelonephritis**
A UTI in which the infection is in the kidney

**R**

**Red blood cells (RBCs)**
RBCs in the urine is called hematuria.

**Regurgitation**
When blood leaks back to the top part of the heart caused by MVP

**Renal dietician**
A dietician with special knowledge and experience in kidney disease

**Renin**
An enzyme produced in the kidneys

**Renin-angiotensin-aldosterone system**
A hormone system in the body that regulates blood pressure and fluid balance
S

Satiety
Feeling full; a common side effect of severe PLD

Sclerose
To harden

Sex chromosomes
The chromosomes that contain genes that determine gender

Sonogram
See ultrasound

Spontaneous mutation
A mutation that arises naturally and is not inherited from parents; also called a de novo

Systolic pressure
The top/first number of the blood pressure reading; it measures the pressure when the heart is pumping

T

Therapeutic coil
A device surgically placed in an aneurysm to repair it

Total kidney volume (TKV)
The total volume your kidney holds and is typically measured by MRI

Truncating mutation
A change in the DNA that can truncate or shorten the protein

Tuberous sclerosis complex
A rare, multisystem genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin; can affect infants who have ADPKD

Tubules
The filtering part of the kidney

United Network for Organ Sharing (UNOS)
The organization that sets transplantation policy and who operates NOTA (see National Organ Procurement and Transplantation Network)

Ureeters
The tubes from the kidneys to the bladder

Urethra
The tube that goes from the bladder to the outside

Uric acid
A common type of crystal that can lead to kidney stones

Urinalysis
An analysis of the urine to determine the type of bacteria that is causing infection

Urinary tract infection (UTI)
An infection caused by bacteria in the bladder, kidneys or cysts

Urine
Liquid by-product of the body secreted by the kidneys

Urine citrate
A substance that prevents formation of kidney stones; it may be decreased in some PKD patients

Venous catheter
A tube inserted into a vein in your neck, chest, or groin area; not intended for long-term use

White blood cells (WBCs)
WBCs are typically present in the urine in small numbers; large numbers in the urine could suggest a UTI

U

Ultrasound
The most common and least costly screening method for PKD; a screening method that uses sound waves to develop images of the inside of the body